



Supplementary Figures:




Supplementary Figure 1| Manhattan plot of the association evidence in discovery


GWAS stage. The genome-wide P values from the Cochran-Armitage trend test on 803,202 SNPs in 2,033 NSCLP cases and 4,051 controls of Chinese Han ancestry are presented. The chromosomal distribution of all P values (as $-\log_{10}P$ values) is shown for each chromosome depicted in a different color. The red horizontal line presents a P value threshold of 10^{-8} .



Supplementary Figure 2| The principal components analyses (PCA) were performed in 6,147 unrelated samples (2,096 NSCLP cases and 4,051 controls) in the discovery GWAS stage.




SupplementaryFigure3| Quantile-quantile (Q-Q) plots for the observed P values (using logistic regression test) from discovery GWAS analysis in 2,033 NSCLP cases and 4,051 controls versus the expected null distribution of P value for association. The plot in purple is for the P values of all SNPs. The genomic inflation factor ($\lambda_{GC} = 1.04$) shown in purple for all the SNPs passing QC.




Supplementary Figure 4 | Summary of significant associated loci with NSCL/P in different populations. Different colors represent the shared common loci or unique loci among the three groups. Multi-ethnic group include at least two races, such as European and Asian.


(a): 2p25.1 (rs287982)




(b): 4p16.2 (rs1907989)




(c): 4q28.1 (rs908822)




(d): 5p12 (rs10462065)




(e): 6p24.3 (rs9381107)




(f): 8p11.23 (rs13317)




(g): 8q22.1 (rs957448)




(h): 9q22.32 (rs10512248)




(i): 12q13.13 (rs3741442)




(j): 12q13.2 (rs705704)




(k): 12q21.1 (rs2304269)




(l): 14q22.1 (rs7148069)



(m): 14q32.13 (rs1243572)




(n): 17q21.32 (rs1838105)



Supplementary Figure 5 | The scatter plots of the association evidence within 14 loci for NSCLP identified in the current study. The 14 loci are as following: a: 2p25.1 (rs287982); b: 4p16.2 (rs1907989); c: 4q28.1 (rs908822); d: 5p12 (rs10462065); e: 6p24.3 (rs9381107); f: 8p11.23 (rs13317); g: 8q22.1 (rs957448); h: 9q22.32 (rs10512248); i: 12q13.13 (rs3741442); j: 12q13.2 (rs705704); k: 12q21.1 (rs2304269); l: 14q22.1 (rs7148069); m: 14q32.13 (rs1243572); n: 17q21.32 (rs1838105). The P values of SNPs (shown as $-\log_{10}$ values in y-axis, obtained using the Cochran-Armitage trend test) were plotted against their chromosomal map positions (x -axis). The color of each SNP spot reflects its r^2 with the top SNP (large purple diamond) within each association locus, changing from red to blue. Estimated recombination rates were plotted in light blue. Gene annotations were adapted from the University of California at Santa Cruz Genome Browser (<http://genome.ucsc.edu/>).


a.

RAD54B




b.

RPS26



c.

FAM49A



Supplementary Figure 6 | Expression studies in the mouse. Immunohistochemistry on mouse embryos from E13.5 to E16.5 shows: a. Rad54b localized in the nucleus of the palatal mesenchymal cells and epithelium cells (C-H) including the MEE during palatal fusion on E14.5 (D). Rad54b expression in palatal tissues increased with development (B, D, F, H). Rps26 localized in the cytoplasm of palatal mesenchymal cells and epithelium cells (A-H) including the MEE during palatal fusion on E14.5 (D). b. Rps26 showed increased expression from E13.5 to E15.5 (A-F) but decreased at E16.5 (G, H). c. Fam49a localized in the nucleus of palatal mesenchymal cells and epithelium cells (A-H). Positive results were stronger at E16.5 in palatal tissues (G, H). n =5; p, palatal shelf; t, tongue; Scale bars: black, 200 μ m; green, 50 μ m. B, D, F and H are the magnification of the palate in A, C, E and G.

Supplementary Tables:

Supplementary Table 1. Samples summary in the genome-wide association and replication studies.

Stage	Cohort	Ethnicity	Phenotype	Cases		Controls	
				Sample size	Male/Female (%)	Sample size	Male/Female (%)
GWAS	cohort 1	Chinese	NSCLP	2,096	72.0/28.0	4,051	58.7/41.3
Stage 2	cohort 2	Chinese	NSCLP	1,346	72.8/27.2	4,542	65.7/34.3
Stage 3	cohort 3	Chinese	NSCLO	1,104	61.6/38.4	3,312*	51.8/48.2
	cohort 4	Chinese	NSCPO	1,104	41.6/58.4	3,312*	51.8/48.2
Stage 4	cohort 5	Central European	NSCL/P	399	62.4/37.6	1,318	50.8/49.2
	cohort 6	Asian	NSCL/P	861 case-parent trios	64.5/35.5	NA	NA
	cohort 7	European American	NSCL/P	557 case-parent trios	64.8/36.2	NA	NA

NSCLP: non-syndromic cleft lip with palate; NSCLO: non-syndromic cleft lip only;

NSCPO: non-syndromic cleft palate only; NSCL/P: non-syndromic cleft lip with or without palate.

*The 3,312 controls were shared in cohort 3 and 4.

Supplementary Table 2. Association results of 146 SNPs in GWAS, NSCLP Replication and Meta analysis of NSCLP.

Loci	SNP	BP (hg19)	Alleles	GWAS				NSCLP Replication				Meta analysis		
				F_A	F_U	P	OR	F_A	F_U	P	OR	P(F)	OR(F)	P _{het} *
1p31.3	rs7554547	11973888	G/A	0.45	0.52	2.89E-05	0.78 (0.72-0.84)	0.47	0.47	9.39E-01	1.00 (0.91-1.09)	5.47E-07	0.86	0.0000
1p36.13	rs9439713	18972776	A/G	0.06	0.04	2.05E-06	1.56 (1.31-1.86)	0.05	0.04	2.06E-01	1.14 (0.93-1.39)	5.87E-06	1.36	0.0453
1p36.13	rs742071	18979874	A/C	0.06	0.04	4.73E-05	1.47 (1.24-1.74)	0.05	0.04	9.17E-03	1.30 (1.01-1.59)	4.26E-07	1.40	0.4859
1p36.13	rs11582254	20018077	A/G	0.37	0.42	1.84E-06	0.80 (0.74-0.87)	0.40	0.41	2.96E-01	0.95 (0.87-1.04)	8.69E-07	0.86	0.0106
1p36.13	rs1883567	20020466	A/C	0.36	0.41	1.02E-05	0.81 (0.75-0.88)	0.39	0.40	4.01E-01	0.96 (0.88-1.05)	8.13E-06	0.88	0.0139
1p32.2	rs6588607	56586286	A/C	0.22	0.25	5.70E-06	0.83 (0.76-0.91)	0.24	0.24	8.86E-01	1.01 (0.91-1.11)	3.78E-03	0.91	0.0152
1p32.2	rs1331862	56642998	G/A	0.23	0.26	3.52E-06	0.83 (0.76-0.91)	0.26	0.25	3.16E-01	1.05 (0.95-1.16)	2.22E-02	0.93	0.0025
1p31.1	rs277354	75291073	G/A	0.23	0.26	4.13E-05	0.86 (0.79-0.94)	0.25	0.25	8.47E-01	0.99 (0.90-1.09)	7.86E-03	0.91	0.0681
1p31.1	rs7367789	75357094	A/G	0.21	0.24	1.67E-05	0.84 (0.77-0.92)	0.23	0.23	9.62E-01	1.00 (0.90-1.11)	4.41E-03	0.91	0.0319
1p22.1	rs4147827	94548080	C/G	0.08	0.05	4.86E-05	1.41 (1.21-1.64)	0.08	0.06	3.98E-03	1.28 (1.08-1.51)	1.89E-07	1.35	0.5255
1p22.1	rs17461953	94551450	C/A	0.08	0.05	2.68E-05	1.42 (1.22-1.65)	0.08	0.06	3.01E-03	1.29 (1.09-1.52)	7.04E-08	1.36	0.5006
1p22.1	rs481931	94570016	A/C	0.33	0.37	4.82E-06	0.83 (0.77-0.90)	0.33	0.39	2.79E-08	0.77 (0.71-0.85)	1.06E-12	0.80	0.3687
1p22.1	rs4147803	94582293	G/C	0.29	0.33	1.22E-06	0.81 (0.75-0.88)	0.29	0.34	2.27E-06	0.80 (0.73-0.88)	7.97E-12	0.81	0.8369
1p13.3	rs12047887	111144007	A/G	0.17	0.15	4.35E-05	1.15 (1.04-1.28)	0.17	0.14	2.16E-04	1.25 (1.11-1.40)	7.78E-06	1.19	0.4277
1p13.3	rs4839542	111155595	A/G	0.16	0.14	3.44E-05	1.19 (1.07-1.32)	0.16	0.13	1.41E-03	1.22 (1.08-1.38)	6.74E-06	1.20	0.8090
1q23.3	rs10918593	162030654	G/A	0.33	0.29	1.31E-05	1.22 (1.12-1.32)	0.31	0.31	6.58E-01	1.02 (0.93-1.12)	1.19E-04	1.13	0.0147
1q32.2	rs861020	209977111	A/G	0.24	0.19	6.38E-12	1.34 (1.23-1.47)	0.23	0.19	6.63E-06	1.27 (1.15-1.41)	1.30E-14	1.31	0.5428
1q32.2	rs642961	209989270	A/G	0.24	0.19	3.86E-12	1.35 (1.23-1.48)	0.23	0.19	2.23E-06	1.29 (1.16-1.43)	2.76E-15	1.32	0.6061
1q32.2	rs2064163	210048819	A/C	0.38	0.44	1.04E-09	0.77 (0.71-0.83)	0.38	0.44	8.18E-09	0.77 (0.71-0.84)	8.60E-19	0.77	0.9625
1q32.2	rs9430019	210050794	A/G	0.31	0.26	1.77E-07	1.27 (1.17-1.38)	0.30	0.26	2.58E-05	1.23 (1.12-1.35)	1.68E-12	1.25	0.6420
1q32.2	rs11583395	218841163	A/G	0.49	0.44	4.04E-05	1.21 (1.12-1.30)	0.47	0.46	2.66E-01	1.05 (0.96-1.15)	1.11E-05	1.14	0.0378
1q32.2	rs201830371	218845278	A/G	0.49	0.44	5.57E-05	1.20 (1.12-1.30)	0.47	0.47	7.87E-01	1.01 (0.93-1.10)	1.42E-04	1.12	0.0098

2p25.1	rs287980	9971366	G/A	0.23	0.27	1.99E-05	0.82 (0.75-0.89)	0.23	0.27	5.54E-04	0.84 (0.76-0.93)	1.94E-08	0.83	0.8120
2p25.1	rs287982	9972442	G/A	0.23	0.27	1.58E-05	0.82 (0.75-0.89)	0.23	0.27	2.28E-04	0.83 (0.75-0.92)	6.15E-09	0.82	0.8981
2p24.2	rs10172734	16733054	G/A	0.26	0.32	3.85E-13	0.76 (0.70-0.83)	0.26	0.33	1.58E-11	0.72 (0.65-0.79)	2.89E-20	0.74	0.4992
2p24.2	rs7552	16733928	A/G	0.24	0.30	1.57E-14	0.74 (0.68-0.81)	0.24	0.31	5.64E-12	0.71 (0.64-0.78)	5.83E-22	0.73	0.5814
2p22.2	rs7590255	37990079	G/A	0.03	0.02	2.73E-06	1.83 (1.43-2.34)	0.02	0.02	1.26E-01	1.25 (0.94-1.67)	3.71E-06	1.56	0.0896
2q21.1	rs17491637	130176577	A/G	0.12	0.16	1.82E-08	0.71 (0.63-0.80)	0.16	0.15	3.60E-01	1.06 (0.94-1.19)	4.89E-04	0.86	0.0000
2q32.1	rs11677862	184898361	A/G	0.38	0.42	1.17E-05	0.82 (0.76-0.89)	0.41	0.41	8.72E-01	0.99 (0.91-1.09)	1.26E-04	0.89	0.0070
2q32.1	rs12623132	184954425	A/C	0.40	0.44	2.10E-06	0.83 (0.77-0.90)	0.41	0.43	1.63E-01	0.94 (0.86-1.03)	1.00E-05	0.88	0.0789
2q35	rs6734545	220653996	A/C	0.20	0.18	8.61E-05	1.16 (1.05-1.27)	0.21	0.17	4.61E-05	1.25 (1.13-1.40)	8.03E-07	1.20	0.3864
2q37.1	rs77866552	233552664	A/G	0.02	0.04	1.73E-06	0.50 (0.39-0.64)	0.03	0.04	8.74E-02	0.81 (0.64-1.03)	7.08E-07	0.64	0.0165
3p24.3	rs78991648	17152071	A/G	0.22	0.26	6.30E-05	0.83 (0.76-0.90)	0.26	0.24	3.64E-02	1.11 (1.01-1.23)	8.23E-02	0.94	0.0000
3p23	rs1395165	31178850	A/G	0.42	0.47	7.82E-05	0.83 (0.77-0.89)	0.44	0.44	7.58E-01	1.01 (0.93-1.11)	4.65E-04	0.90	0.0021
3p23	rs12485312	31219954	A/G	0.41	0.46	5.96E-05	0.83 (0.77-0.90)	0.43	0.43	8.86E-01	1.01 (0.92-1.10)	5.27E-04	0.90	0.0049
3q12.1	rs1038294	99503728	A/G	0.13	0.17	1.18E-07	0.73 (0.66-0.81)	0.15	0.16	2.12E-01	0.93 (0.82-1.05)	4.47E-07	0.81	0.0127
3q12.1	rs1688766	99647850	A/G	0.13	0.17	1.32E-07	0.73 (0.65-0.81)	0.15	0.16	2.28E-01	0.93 (0.82-1.05)	4.83E-07	0.81	0.0113
3q13.31	rs9847858	117141815	A/G	0.32	0.35	8.86E-05	0.85 (0.78-0.92)	0.33	0.33	5.87E-01	1.03 (0.94-1.12)	6.63E-03	0.92	0.0068
3q26.2	rs10936656	170568001	A/C	0.34	0.37	7.47E-05	0.86 (0.79-0.93)	0.36	0.37	2.53E-01	0.95 (0.87-1.04)	3.30E-04	0.90	0.1672
3q29	rs17597256	196767854	G/A	0.24	0.27	7.80E-05	0.85 (0.78-0.93)	0.24	0.27	1.24E-02	0.88 (0.80-0.97)	1.48E-05	0.86	0.7255
3q29	rs7649443	196931821	A/G	0.24	0.27	8.71E-05	0.86 (0.79-0.94)	0.25	0.27	4.39E-03	0.87 (0.78-0.96)	9.23E-06	0.86	0.9600
4p16.2	rs34246903	4794195	C/A	0.38	0.43	2.57E-05	0.82 (0.76-0.89)	0.40	0.43	1.09E-02	0.89 (0.82-0.97)	4.45E-08	0.85	0.2344
4p16.2	rs1907989	4818925	A/G	0.46	0.51	2.29E-06	0.81 (0.75-0.87)	0.48	0.50	1.94E-02	0.90 (0.83-0.98)	1.58E-08	0.85	0.1130
4q28.1	rs7692299	124710584	A/G	0.09	0.06	3.72E-07	1.49 (1.30-1.73)	0.07	0.07	2.60E-01	1.10 (0.93-1.31)	9.29E-07	1.32	0.0180
4q28.1	rs908822	124906257	A/G	0.10	0.07	6.13E-07	1.46 (1.28-1.66)	0.10	0.09	4.46E-02	1.16 (1.00-1.34)	4.33E-08	1.31	0.0545
4q31.3	rs7686589	151337243	A/G	0.37	0.33	3.08E-05	1.18 (1.09-1.28)	0.36	0.35	4.63E-01	1.03 (0.95-1.13)	3.05E-04	1.12	0.0563
4q31.3	rs66509882	151543429	C/A	0.37	0.33	3.41E-06	1.20 (1.11-1.30)	0.35	0.35	9.55E-01	1.00 (0.92-1.10)	4.71E-04	1.11	0.0102
4q32.1	rs4417922	157006346	G/A	0.30	0.34	1.55E-06	0.82 (0.76-0.89)	0.32	0.32	9.49E-01	1.00 (0.91-1.09)	4.59E-04	0.90	0.0085

4q34.3	rs2333571	177761552	A/G	0.34	0.36	7.18E-05	0.89 (0.82-0.96)	0.35	0.38	3.41E-02	0.91 (0.83-0.99)	3.33E-04	0.90	0.8141
4q34.3	rs13124707	177802518	G/A	0.35	0.38	6.52E-05	0.88 (0.82-0.96)	0.36	0.39	7.10E-03	0.88 (0.81-0.97)	4.48E-05	0.88	0.9965
5p12	rs10462065	44068846	A/C	0.24	0.20	3.51E-07	1.26 (1.15-1.38)	0.23	0.20	2.04E-03	1.18 (1.06-1.31)	1.12E-08	1.22	0.4835
5p12	rs4242107	44129083	A/G	0.44	0.40	6.08E-07	1.17 (1.09-1.26)	0.43	0.40	7.44E-03	1.13 (1.03-1.23)	1.32E-06	1.15	0.5979
5p12	rs10462084	44901349	G/A	0.03	0.05	2.18E-05	0.68 (0.55-0.83)	0.04	0.05	3.78E-02	0.80 (0.64-0.99)	2.52E-05	0.73	0.3877
6p24.3	rs7771515	9442330	A/G	0.35	0.40	2.41E-09	0.80 (0.74-0.87)	0.38	0.40	1.17E-01	0.93 (0.85-1.02)	2.33E-07	0.86	0.0322
6p24.3	rs9381107	9469238	A/G	0.31	0.37	1.97E-09	0.79 (0.73-0.86)	0.33	0.36	1.40E-02	0.89 (0.81-0.98)	2.72E-09	0.83	0.0900
6p24.3	rs11965246	9959207	C/A	0.04	0.07	1.21E-05	0.61 (0.51-0.73)	0.07	0.06	2.16E-01	1.12 (0.94-1.33)	4.09E-03	0.83	0.0000
6p23	rs12203226	14951008	A/C	0.43	0.39	3.24E-06	1.20 (1.11-1.30)	0.39	0.40	2.17E-01	0.95 (0.87-1.03)	6.66E-03	1.08	0.0006
7p21.2	rs10260512	14856700	A/G	0.40	0.44	4.98E-05	0.87 (0.80-0.94)	0.40	0.41	2.39E-01	0.95 (0.87-1.04)	4.61E-04	0.90	0.2182
7p21.1	rs76523544	19308308	C/A	0.08	0.11	2.17E-05	0.67 (0.58-0.77)	0.10	0.09	6.88E-01	1.03 (0.89-1.19)	9.80E-05	0.82	0.0000
7q36.2	rs10256809	155079596	A/G	0.07	0.10	3.19E-07	0.65 (0.56-0.75)	0.10	0.09	2.68E-01	1.09 (0.94-1.26)	6.84E-04	0.84	0.0000
8p22	rs17227506	13458794	A/G	0.39	0.44	8.24E-06	0.82 (0.76-0.89)	0.40	0.42	1.46E-01	0.94 (0.86-1.02)	2.70E-06	0.87	0.0575
8p11.23	rs13317	38269514	G/A	0.30	0.34	4.10E-06	0.83 (0.77-0.90)	0.32	0.35	7.43E-03	0.88 (0.80-0.97)	3.96E-08	0.85	0.4601
8p11.23	rs3925	38281658	A/G	0.27	0.32	1.47E-06	0.81 (0.74-0.88)	0.30	0.32	3.24E-02	0.90 (0.82-0.99)	2.66E-07	0.85	0.1398
8q21.3	rs12543318	88868340	A/C	0.32	0.38	2.43E-07	0.78 (0.72-0.84)	0.33	0.37	7.83E-04	0.86 (0.78-0.94)	8.80E-12	0.81	0.2050
8q21.3	rs1034832	88918331	C/A	0.31	0.36	5.92E-07	0.79 (0.73-0.85)	0.32	0.35	1.65E-03	0.86 (0.79-0.95)	1.35E-10	0.82	0.2243
8q22.1	rs12681366	95401265	G/A	0.44	0.49	2.95E-06	0.82 (0.76-0.88)	0.44	0.48	2.48E-04	0.85 (0.78-0.93)	2.35E-10	0.83	0.5965
8q22.1	rs957448	95541302	G/A	0.44	0.50	3.78E-10	0.78 (0.72-0.84)	0.46	0.49	7.59E-04	0.86 (0.79-0.94)	9.60E-13	0.81	0.1260
8q22.2	rs11774066	99455311	A/G	0.42	0.38	8.65E-05	1.18 (1.09-1.28)	0.42	0.39	3.85E-03	1.14 (1.04-1.24)	3.39E-07	1.16	0.6166
8q22.2	rs1487022	100529826	A/C	0.44	0.39	5.64E-05	1.19 (1.10-1.28)	0.44	0.41	1.43E-03	1.15 (1.06-1.26)	7.84E-08	1.17	0.7214
8q24.12	rs1993392	121240646	G/A	0.13	0.16	6.63E-06	0.78 (0.70-0.87)	0.15	0.15	4.74E-01	0.96 (0.85-1.08)	1.57E-04	0.85	0.0319
8q24.21	rs7845615	129888794	A/G	0.22	0.18	5.11E-06	1.28 (1.17-1.41)	0.20	0.17	8.59E-05	1.25 (1.12-1.39)	1.03E-10	1.27	0.8110
8q24.21	rs7017252	129950844	A/G	0.08	0.05	3.27E-06	1.59 (1.36-1.85)	0.07	0.05	4.18E-08	1.62 (1.36-1.93)	8.47E-16	1.60	0.8960
9p24.1	rs327753	7793309	G/A	0.28	0.32	8.34E-05	0.83 (0.77-0.90)	0.30	0.30	9.01E-01	1.01 (0.92-1.11)	1.45E-03	0.90	0.0094
9p24.1	rs2990600	7796329	C/A	0.27	0.31	3.47E-05	0.82 (0.76-0.89)	0.30	0.29	7.55E-01	1.02 (0.92-1.12)	1.26E-03	0.90	0.0043

9p23	rs408960	9069839	G/A	0.45	0.42	5.34E-05	1.14 (1.05-1.23)	0.45	0.45	8.99E-01	1.01 (0.92-1.10)	1.02E-02	1.08	0.0717
9p23	rs324475	9077607	C/A	0.44	0.41	9.27E-05	1.13 (1.05-1.22)	0.44	0.44	7.77E-01	1.01 (0.93-1.10)	1.05E-02	1.08	0.1111
9p23	rs77401103	10546603	G/A	0.06	0.09	5.74E-07	0.64 (0.55-0.75)	0.08	0.09	7.84E-01	0.98 (0.84-1.14)	3.54E-05	0.79	0.0009
9p23	rs542733	14098867	G/A	0.40	0.45	1.75E-05	0.84 (0.76-0.90)	0.43	0.42	5.58E-01	1.03 (0.94-1.12)	2.31E-03	0.91	0.0024
9p23	rs498010	14116484	A/G	0.29	0.33	6.24E-05	0.83 (0.77-0.90)	0.30	0.31	9.47E-01	1.00 (0.91-1.10)	9.05E-04	0.90	0.0136
9p21.3	rs35825512	20167602	A/G	0.03	0.05	5.39E-05	0.63 (0.51-0.77)	0.04	0.03	1.38E-02	1.32 (1.06-1.64)	1.43E-01	0.89	0.0000
9p21.3	rs7863754	20168739	A/G	0.03	0.05	4.11E-05	0.63 (0.51-0.78)	0.04	0.03	9.06E-03	1.34 (1.07-1.67)	1.88E-01	0.90	0.0000
9q22.2	rs7871395	92209587	A/G	0.30	0.26	4.54E-05	1.23 (1.13-1.34)	0.29	0.26	1.07E-03	1.17 (1.07-1.29)	6.06E-09	1.21	0.5782
9q22.32	rs10512248	98259703	C/A	0.29	0.34	1.80E-07	0.79 (0.73-0.86)	0.30	0.33	3.19E-03	0.87 (0.79-0.95)	5.10E-10	0.82	0.2026
9q22.32	rs28361526	98295863	A/G	0.30	0.34	1.65E-05	0.83 (0.77-0.90)	0.31	0.34	3.02E-02	0.90 (0.82-0.99)	1.95E-06	0.86	0.2949
9q33.1	rs13294988	119099873	G/A	0.47	0.43	1.23E-05	1.17 (1.08-1.26)	0.45	0.43	2.22E-02	1.11 (1.02-1.21)	6.68E-06	1.14	0.4994
10q24.2	rs474558	99695194	A/C	0.26	0.20	1.43E-12	1.40 (1.28-1.53)	0.25	0.26	2.62E-01	0.94 (0.86-1.04)	5.05E-06	1.17	0.0000
10q25.3	rs6585429	118893231	G/A	0.39	0.44	4.92E-08	0.81 (0.75-0.87)	0.39	0.45	2.22E-06	0.81 (0.74-0.88)	7.14E-13	0.81	0.9967
11q13.3	rs12792211	69025553	A/G	0.26	0.23	9.52E-05	1.21 (1.11-1.32)	0.26	0.24	1.69E-01	1.07 (0.97-1.18)	4.90E-05	1.15	0.1364
12q13.13	rs3741442	53346750	G/A	0.46	0.41	1.17E-06	1.22 (1.13-1.32)	0.46	0.41	3.36E-06	1.23 (1.13-1.34)	3.72E-12	1.22	0.9598
12q13.2	rs705704	56435412	A/G	0.27	0.23	4.39E-05	1.22 (1.12-1.33)	0.28	0.24	5.97E-05	1.22 (1.11-1.34)	1.29E-09	1.22	0.9839
12q21.1	rs2304269	72080272	G/A	0.38	0.44	1.07E-07	0.79 (0.73-0.85)	0.41	0.45	1.12E-04	0.84 (0.77-0.92)	1.32E-12	0.81	0.3903
12q21.1	rs7967428	72089040	G/A	0.38	0.44	1.63E-07	0.79 (0.73-0.85)	0.41	0.45	1.57E-04	0.84 (0.77-0.92)	3.08E-12	0.81	0.3871
12q24.11	rs2188380	111386127	G/A	0.12	0.17	5.75E-09	0.67 (0.60-0.74)	0.15	0.15	9.18E-01	1.01 (0.89-1.14)	1.49E-07	0.80	0.0000
12q24.11	rs12229654	111414461	C/A	0.13	0.18	2.59E-08	0.68 (0.61-0.76)	0.15	0.16	4.22E-01	0.95 (0.85-1.07)	1.06E-08	0.79	0.0000
12q24.11	rs4766453	111692124	A/G	0.51	0.47	5.13E-05	1.20 (1.12-1.30)	0.49	0.47	1.92E-01	1.06 (0.97-1.15)	7.76E-06	1.14	0.0563
12q24.13	rs11066150	112518803	A/G	0.34	0.42	5.21E-09	0.72 (0.67-0.78)	0.35	0.37	7.32E-02	0.92 (0.84-1.01)	3.41E-13	0.80	0.0006
12q24.13	rs12229892	112923393	A/G	0.41	0.48	7.86E-09	0.75 (0.69-0.80)	0.43	0.44	2.92E-01	0.95 (0.87-1.04)	1.84E-10	0.83	0.0000
13q31.1	rs9545308	80639405	A/C	0.15	0.12	4.09E-05	1.30 (1.17-1.45)	0.14	0.11	2.34E-04	1.27 (1.12-1.44)	2.00E-09	1.29	0.8103
14q13.2	rs1168980	36400983	C/A	0.16	0.20	3.49E-05	0.80 (0.73-0.88)	0.20	0.19	1.63E-01	1.08 (0.97-1.21)	2.18E-02	0.92	0.0005
14q13.2	rs17103683	36426134	A/G	0.18	0.21	7.09E-06	0.79 (0.71-0.86)	0.21	0.20	1.65E-01	1.08 (0.97-1.20)	7.12E-03	0.91	0.0000

14q13.3	rs1956424	37531902	A/G	0.27	0.24	2.33E-07	1.19 (1.10-1.30)	0.25	0.25	9.29E-01	1.01 (0.91-1.11)	1.91E-03	1.11	0.0265
14q13.3	rs10133673	37537352	G/A	0.27	0.24	4.49E-07	1.19 (1.09-1.29)	0.25	0.23	4.25E-03	1.16 (1.05-1.28)	1.44E-06	1.17	0.8053
14q22.1	rs7148069	51839645	A/G	0.23	0.19	1.94E-05	1.27 (1.16-1.40)	0.22	0.20	7.21E-03	1.16 (1.04-1.28)	1.69E-08	1.22	0.2538
14q22.1	rs10134081	51848843	G/A	0.12	0.09	5.00E-06	1.41 (1.25-1.59)	0.12	0.10	8.72E-02	1.13 (0.98-1.29)	1.23E-07	1.28	0.0382
14q24.3	rs9671386	75151047	G/A	0.27	0.30	7.93E-05	0.87 (0.80-0.94)	0.28	0.28	9.95E-01	1.00 (0.91-1.10)	1.12E-02	0.92	0.0534
14q32.13	rs1243572	95379499	G/A	0.48	0.42	1.37E-07	1.26 (1.17-1.36)	0.45	0.42	6.09E-03	1.13 (1.04-1.23)	3.52E-10	1.20	0.1138
14q32.13	rs1243573	95379583	C/A	0.48	0.42	2.83E-07	1.25 (1.16-1.35)	0.45	0.42	7.30E-03	1.13 (1.03-1.23)	8.61E-10	1.20	0.1178
15q22.2	rs78512626	61432877	C/A	0.12	0.15	8.05E-06	0.76 (0.67-0.85)	0.14	0.15	3.84E-01	0.95 (0.84-1.07)	7.02E-05	0.84	0.0261
15q24.1	rs2289187	74744399	G/A	0.55	0.48	2.73E-08	1.33 (1.24-1.44)	0.48	0.50	1.34E-01	0.94 (0.86-1.02)	3.86E-11	1.21	0.0005
15q24.1	rs6495117	74899500	G/A	0.45	0.52	2.95E-08	0.75 (0.69-0.81)	0.48	0.50	1.70E-01	0.94 (0.86-1.03)	6.29E-11	0.83	0.0005
16p13.3	rs2283487	3969886	G/A	0.42	0.47	3.18E-06	0.83 (0.76-0.89)	0.43	0.47	3.91E-05	0.83 (0.76-0.91)	1.27E-10	0.83	0.9121
16p13.3	rs17136624	3996282	A/G	0.25	0.22	8.43E-05	1.21 (1.11-1.32)	0.27	0.23	3.11E-06	1.28 (1.15-1.42)	3.82E-10	1.24	0.5269
16p13.3	rs4786640	5243669	C/A	0.52	0.48	9.15E-05	1.19 (1.10-1.28)	0.48	0.49	2.78E-01	0.95 (0.87-1.04)	6.89E-03	1.08	0.0005
16p13.11	rs7198766	16105965	G/A	0.24	0.29	7.95E-05	0.78 (0.71-0.85)	0.26	0.25	8.41E-02	1.09 (0.99-1.20)	1.92E-03	0.90	0.0000
16p13.11	rs7188937	16118620	A/C	0.24	0.29	6.91E-05	0.78 (0.72-0.85)	0.26	0.25	2.01E-01	1.07 (0.97-1.18)	6.08E-04	0.89	0.0000
16q22.2	rs217181	72114002	A/G	0.32	0.29	2.05E-05	1.15 (1.06-1.25)	0.32	0.31	5.06E-02	1.10 (1.00-1.20)	1.34E-04	1.13	0.5508
17p13.1	rs2872615	8914693	G/A	0.43	0.48	7.45E-06	0.80 (0.74-0.87)	0.43	0.47	1.06E-04	0.84 (0.77-0.92)	8.81E-12	0.82	0.5224
17p13.1	rs1880646	8929845	A/G	0.52	0.46	4.98E-06	1.25 (1.16-1.35)	0.52	0.48	2.60E-04	1.17 (1.08-1.28)	1.69E-11	1.22	0.4104
17q21.32	rs4968247	44988703	A/G	0.37	0.41	4.11E-06	0.84 (0.78-0.91)	0.37	0.41	2.43E-05	0.83 (0.76-0.90)	8.70E-10	0.83	0.8605
17q21.32	rs1838105	45008935	A/G	0.45	0.39	1.84E-07	1.26 (1.17-1.36)	0.42	0.38	3.48E-04	1.17 (1.08-1.28)	1.31E-11	1.22	0.3543
17q22	rs12951993	54760614	A/G	0.36	0.32	1.19E-05	1.21 (1.12-1.31)	0.36	0.33	2.88E-02	1.11 (1.01-1.21)	5.26E-07	1.16	0.2119
17q22	rs227731	54773238	C/A	0.36	0.32	1.74E-05	1.22 (1.12-1.32)	0.36	0.32	1.19E-03	1.16 (1.06-1.27)	8.83E-09	1.19	0.5623
18q11.2	rs3903236	22122490	C/A	0.29	0.33	2.87E-05	0.82 (0.76-0.89)	0.32	0.32	9.35E-01	1.00 (0.91-1.09)	3.64E-04	0.89	0.0077
18q11.2	rs79280643	22126108	A/G	0.29	0.33	6.64E-05	0.82 (0.76-0.90)	0.32	0.32	7.53E-01	0.99 (0.90-1.08)	2.79E-04	0.89	0.0136
18q22.3	rs117386717	69155820	G/A	0.02	0.03	7.86E-07	0.56 (0.43-0.72)	0.03	0.04	5.89E-01	0.94 (0.74-1.19)	8.42E-04	0.74	0.0111
19p13.11	rs739461	19715794	A/G	0.21	0.25	4.52E-05	0.81 (0.74-0.89)	0.22	0.23	3.37E-01	0.95 (0.86-1.05)	4.24E-05	0.87	0.0456

20q12	rs6129653	39275603	A/G	0.35	0.31	2.99E-06	1.21 (1.12-1.31)	0.35	0.30	5.78E-07	1.26 (1.15-1.39)	8.57E-12	1.23	0.5970
20q13.2	rs6126344	50407502	A/C	0.37	0.41	1.80E-05	0.87 (0.81-0.94)	0.38	0.42	2.33E-05	0.83 (0.76-0.90)	5.66E-08	0.85	0.4962
21q22.3	rs2018054	45703660	C/A	0.11	0.14	4.51E-05	0.77 (0.68-0.86)	0.13	0.13	8.53E-01	0.99 (0.87-1.12)	5.05E-04	0.86	0.0126
21q22.3	rs933150	45712588	A/G	0.18	0.21	3.77E-05	0.81 (0.73-0.89)	0.19	0.20	3.26E-01	0.95 (0.85-1.06)	1.06E-04	0.87	0.0684
22q11.21	rs7287092	19561423	A/G	0.19	0.16	9.64E-05	1.25 (1.13-1.37)	0.18	0.17	3.85E-01	1.05 (0.94-1.18)	1.16E-04	1.16	0.0532
22q11.21	rs2073764	19799410	A/G	0.01	0.04	2.61E-14	0.31 (0.23-0.42)	0.04	0.05	3.76E-01	0.91 (0.73-1.12)	2.20E-07	0.63	0.0000
22q12.1	rs8135014	28046561	A/G	0.14	0.11	6.51E-05	1.26 (1.12-1.41)	0.13	0.13	6.58E-01	1.03 (0.90-1.17)	9.97E-04	1.15	0.0468
22q12.2	rs36604	30340138	C/A	0.15	0.10	6.34E-07	1.61 (1.43-1.80)	0.13	0.14	1.66E-01	0.91 (0.80-1.04)	2.04E-07	1.25	0.0000
22q12.2	rs5763674	30386358	G/A	0.15	0.10	4.39E-07	1.61 (1.44-1.81)	0.13	0.14	1.76E-01	0.92 (0.81-1.04)	1.22E-07	1.26	0.0000
22q12.2	rs11089442	30689998	A/G	0.38	0.32	1.24E-07	1.33 (1.23-1.44)	0.35	0.36	9.45E-02	0.93 (0.85-1.01)	1.98E-05	1.14	0.0000
22q12.2	rs2839998	30729507	A/G	0.38	0.32	1.28E-07	1.33 (1.23-1.44)	0.35	0.36	8.09E-02	0.92 (0.84-1.01)	2.42E-05	1.14	0.0000
22q12.2	rs2072196	30975513	A/G	0.44	0.38	4.00E-06	1.30 (1.21-1.41)	0.41	0.43	7.46E-02	0.92 (0.85-1.01)	8.20E-05	1.12	0.0000
22q12.2	rs117353193	31010417	A/G	0.05	0.03	1.13E-05	1.92 (1.59-2.32)	0.04	0.05	1.34E-01	0.85 (0.68-1.05)	4.34E-05	1.35	0.0000
22q12.2	rs5753388	31310946	G/A	0.33	0.27	9.21E-06	1.35 (1.24-1.46)	0.29	0.31	8.73E-02	0.92 (0.84-1.01)	1.80E-05	1.14	0.0000
22q12.2	rs1003480	31346752	A/G	0.33	0.26	8.65E-06	1.34 (1.24-1.46)	0.29	0.31	8.46E-02	0.92 (0.84-1.01)	2.66E-05	1.14	0.0000
22q12.2	rs2073856	31663985	A/G	0.40	0.36	2.32E-06	1.19 (1.10-1.29)	0.37	0.36	7.81E-01	1.01 (0.93-1.11)	4.14E-04	1.11	0.0184
22q12.2	rs17220418	31697842	A/G	0.40	0.36	6.08E-06	1.18 (1.09-1.28)	0.37	0.36	6.82E-01	1.02 (0.93-1.11)	5.16E-04	1.11	0.0322
22q12.2	rs2006771	31998612	A/G	0.24	0.18	2.14E-05	1.36 (1.24-1.49)	0.23	0.22	3.42E-01	1.05 (0.95-1.16)	2.54E-08	1.21	0.0009
22q12.3	rs78212183	32213984	G/A	0.11	0.07	1.29E-06	1.60 (1.40-1.83)	0.10	0.09	3.29E-01	1.08 (0.93-1.25)	4.80E-09	1.34	0.0005
22q12.3	rs5756130	36684331	A/G	0.14	0.11	8.41E-05	1.34 (1.20-1.50)	0.14	0.13	3.13E-01	1.07 (0.94-1.21)	6.17E-06	1.21	0.0184

F_A: minor allele frequency in cases; F_U: minor allele frequency in controls; OR: odds ratio.

Alleles: shown as minor allele/major allele.

NSCLP Replication: replication study in 1,346 NSCLP cases and 4,542 controls of Chinese.

Meta analysis: Meta analysis of GWAS and NSCLP Replication.

The P value of GWAS and NSCLP Replication was calculated using logistic regression test

P(F) (The P value using Cochran-Mantel-Haenszel test) and OR(F) were calculated using fixed model.

*P het: P value for heterozygosity using logistic regression test and Bonferroni correction. P het > 0.05 was considered to signify no heterogeneity.

Supplementary Table 3. Association results of 14 novel loci and 3 suggestive loci in GWAS, NSCLP Replication and Meta analysis.

Loci	SNP	BP (hg19)	Alleles	GWAS				NSCLP Replication				Meta analysis		
				F_A	F_U	P	OR	F_A	F_U	P	OR	P(F)	OR(F)	P _{het} *
2p25.1	rs287980	9971366	G/A	0.23	0.27	1.99E-05	0.82 (0.75-0.89)	0.23	0.27	5.54E-04	0.84 (0.76-0.93)	1.94E-08	0.83	0.8120
2p25.1	rs287982	9972442	G/A	0.23	0.27	1.58E-05	0.82 (0.75-0.89)	0.23	0.27	2.28E-04	0.83 (0.75-0.92)	6.15E-09	0.82	0.8981
2q35	rs6734545	220653996	A/C	0.20	0.18	8.61E-05	1.16 (1.05-1.27)	0.21	0.17	4.61E-05	1.25 (1.13-1.40)	8.03E-07	1.20	0.3864
4p16.2	rs34246903	4794195	C/A	0.38	0.43	2.57E-05	0.82 (0.76-0.89)	0.40	0.43	1.09E-02	0.89 (0.82-0.97)	4.45E-08	0.85	0.2344
4p16.2	rs1907989	4818925	A/G	0.46	0.51	2.29E-06	0.81 (0.75-0.87)	0.48	0.50	1.94E-02	0.90 (0.83-0.98)	1.58E-08	0.85	0.1130
4q28.1	rs908822	124906257	A/G	0.10	0.07	6.13E-07	1.46 (1.28-1.66)	0.10	0.09	4.46E-02	1.16 (1.00-1.34)	4.33E-08	1.31	0.0545
5p12	rs10462065	44068846	A/C	0.24	0.20	3.51E-07	1.26 (1.15-1.38)	0.23	0.20	2.04E-03	1.18 (1.06-1.31)	1.12E-08	1.22	0.4835
5p12	rs4242107	44129083	A/G	0.44	0.40	6.08E-07	1.17 (1.09-1.26)	0.43	0.40	7.44E-03	1.13 (1.03-1.23)	1.32E-06	1.15	0.5979
6p24.3	rs9381107	9469238	A/G	0.31	0.37	1.97E-09	0.79 (0.73-0.86)	0.33	0.36	1.40E-02	0.89 (0.81-0.98)	2.72E-09	0.83	0.0900
8p11.23	rs13317	38269514	G/A	0.30	0.34	4.10E-06	0.83 (0.77-0.90)	0.32	0.35	7.43E-03	0.88 (0.80-0.97)	3.96E-08	0.85	0.4601
8q22.1	rs12681366	95401265	G/A	0.44	0.49	2.95E-06	0.82 (0.76-0.88)	0.44	0.48	2.48E-04	0.85 (0.78-0.93)	2.35E-10	0.83	0.5965
8q22.1	rs957448	95541302	G/A	0.44	0.50	3.78E-10	0.78 (0.72-0.84)	0.46	0.49	7.59E-04	0.86 (0.79-0.94)	9.60E-13	0.81	0.1260
8q22.2	rs11774066	99455311	A/G	0.42	0.38	8.65E-05	1.18 (1.09-1.28)	0.42	0.39	3.85E-03	1.14 (1.04-1.24)	3.39E-07	1.16	0.6166
8q22.2	rs1487022	100529826	A/C	0.44	0.39	5.64E-05	1.19 (1.10-1.28)	0.44	0.41	1.43E-03	1.15 (1.06-1.26)	7.84E-08	1.17	0.7214
9q22.32	rs10512248	98259703	C/A	0.29	0.34	1.80E-07	0.79 (0.73-0.86)	0.30	0.33	3.19E-03	0.87 (0.79-0.95)	5.10E-10	0.82	0.2026
9q22.32	rs28361526	98295863	A/G	0.30	0.34	1.65E-05	0.83 (0.77-0.90)	0.31	0.34	3.02E-02	0.90 (0.82-0.99)	1.95E-06	0.86	0.2949
12q13.13	rs3741442	53346750	G/A	0.46	0.41	1.17E-06	1.22 (1.13-1.32)	0.46	0.41	3.36E-06	1.23 (1.13-1.34)	3.72E-12	1.22	0.9598
12q13.2	rs705704	56435412	A/G	0.27	0.23	4.39E-05	1.22 (1.12-1.33)	0.28	0.24	5.97E-05	1.22 (1.11-1.34)	1.29E-09	1.22	0.9839
12q21.1	rs2304269	72080272	G/A	0.38	0.44	1.07E-07	0.79 (0.73-0.85)	0.41	0.45	1.12E-04	0.84 (0.77-0.92)	1.32E-12	0.81	0.3903
12q21.1	rs7967428	72089040	G/A	0.38	0.44	1.63E-07	0.79 (0.73-0.85)	0.41	0.45	1.57E-04	0.84 (0.77-0.92)	3.08E-12	0.81	0.3871
14q22.1	rs7148069	51839645	A/G	0.23	0.19	1.94E-05	1.27 (1.16-1.40)	0.22	0.20	7.21E-03	1.16 (1.04-1.28)	1.69E-08	1.22	0.2538
14q32.13	rs1243572	95379499	G/A	0.48	0.42	1.37E-07	1.26 (1.17-1.36)	0.45	0.42	6.09E-03	1.13 (1.04-1.23)	3.52E-10	1.20	0.1138

14q32.13	rs1243573	95379583	C/A	0.48	0.42	2.83E-07	1.25 (1.16-1.35)	0.45	0.42	7.30E-03	1.13 (1.03-1.23)	8.61E-10	1.20	0.1178
17q21.32	rs4968247	44988703	A/G	0.37	0.41	4.11E-06	0.84 (0.78-0.91)	0.37	0.41	2.43E-05	0.83 (0.76-0.90)	8.70E-10	0.83	0.8605
17q21.32	rs1838105	45008935	A/G	0.45	0.39	1.84E-07	1.26 (1.17-1.36)	0.42	0.38	3.48E-04	1.17 (1.08-1.28)	1.31E-11	1.22	0.3543
20q13.2	rs6126344	50407502	A/C	0.37	0.41	1.80E-05	0.87 (0.81-0.94)	0.38	0.42	2.33E-05	0.83 (0.76-0.90)	5.66E-08	0.85	0.4962

F_A: minor allele frequency in cases; F_U: minor allele frequency in controls; OR: odds ratio.

Alleles: shown as minor allele/major allele.

P(F) and OR(F) were calculated using fixed model.

NSCLP Replication: replication study in 1,346 NSCLP cases and 4,542 controls of Chinese.

Meta analysis: Meta analysis of GWAS and NSCLP Replication.

The P value of GWAS and NSCLP Replication were calculated using logistic regression test

P(F) (The P value using Cochran-Mantel-Haenszel test) and OR(F) were calculated using fixed model.

*P het: P value for heterozygosity using logistic regression test Bonferroni correction. P het > 0.05 was considered to signify no heterogeneity.

Supplementary Table 4. Association results for 22 previously reported NSCL/P loci in GWAS, NSCLP Replication and Meta analysis.

Loci	SNP	BP (hg19)	Gene	Alleles	GWAS				NSCLP Replication				Meta analysis		
					F_A	F_U	P	OR	F_A	F_U	P	OR	P(F)	OR(F)	P _{het} *
1p36.13	rs742071	18979874	<i>PAX7</i>	A/C	0.06	0.04	4.73E-05	1.47 (1.24-1.74)	0.05	0.04	9.17E-03	1.30 (1.07-1.59)	4.26E-07	1.40	0.4859
1p22.1	rs4147827	94548080	<i>ABCA4</i>	C/G	0.08	0.05	4.86E-05	1.41 (1.21-1.64)	0.08	0.06	3.98E-03	1.28 (1.08-1.51)	1.89E-07	1.35	0.5255
1p22.1	rs17461953	94551450	<i>ABCA4</i>	C/A	0.08	0.05	2.68E-05	1.42 (1.22-1.65)	0.08	0.06	3.01E-03	1.29 (1.09-1.52)	7.04E-08	1.36	0.5006
1p22.1	rs481931	94570016	<i>ABCA4</i>	A/C	0.33	0.37	4.82E-06	0.83 (0.77-0.90)	0.33	0.39	2.79E-08	0.77 (0.71-0.85)	1.06E-12	0.80	0.3687
1p22.1	rs4147803	94582293	<i>ABCA4</i>	G/C	0.29	0.33	1.22E-06	0.81 (0.75-0.88)	0.29	0.34	2.27E-06	0.80 (0.73-0.88)	7.97E-12	0.81	0.8369
1q32.2	rs861020	209977111	<i>IRF6</i>	A/G	0.24	0.19	6.38E-12	1.34 (1.23-1.47)	0.23	0.19	6.63E-06	1.27 (1.15-1.41)	1.30E-14	1.31	0.5428
1q32.2	rs642961	209989270	<i>IRF6</i>	A/G	0.24	0.19	3.86E-12	1.35 (1.23-1.48)	0.23	0.19	2.23E-06	1.29 (1.16-1.43)	2.76E-15	1.32	0.6061
1q32.2	rs2064163	210048819	<i>IRF6</i>	A/C	0.38	0.44	1.04E-09	0.77 (0.71-0.83)	0.38	0.44	8.18E-09	0.77 (0.71-0.84)	8.60E-19	0.77	0.9625
1q32.2	rs9430019	210050794	<i>IRF6</i>	A/G	0.31	0.26	1.77E-07	1.27 (1.17-1.38)	0.30	0.26	2.58E-05	1.23 (1.12-1.35)	1.68E-12	1.25	0.6420
2p24.2	rs10172734	16733054	<i>FAM49A</i>	G/A	0.26	0.32	3.85E-13	0.76 (0.70-0.83)	0.26	0.33	1.58E-11	0.72 (0.65-0.79)	2.89E-20	0.74	0.4992
2p24.2	rs7552	16733928	<i>FAM49A</i>	A/G	0.24	0.30	1.57E-14	0.74 (0.68-0.81)	0.24	0.31	5.64E-12	0.71 (0.64-0.78)	5.83E-22	0.73	0.5814
2p21	rs7590268	43540125	<i>THADA</i>	C/A	0.07	0.05	3.02E-04	1.33 (1.14-1.56)	NA	NA	NA	NA	NA	NA	NA
2p21	rs6544647	43578419	<i>THADA</i>	A/G	0.08	0.06	2.33E-05	1.37 (1.18-1.58)	NA	NA	NA	NA	NA	NA	NA
3p11.1	rs10511145	89597679	<i>EPHA3</i>	A/C	0.17	0.20	1.53E-04	0.83 (0.75-0.91)	NA	NA	NA	NA	NA	NA	NA
3q12.1	rs1038294	99503728	<i>COL8A1</i>	A/G	0.13	0.17	1.18E-07	0.73 (0.66-0.81)	0.15	0.16	2.12E-01	0.93 (0.82-1.05)	4.47E-07	0.81	0.0127
3q12.1	rs1688766	99647850	<i>COL8A1</i>	A/G	0.13	0.17	1.32E-07	0.73 (0.65-0.81)	0.15	0.16	2.28E-01	0.93 (0.82-1.05)	4.83E-07	0.81	0.0113
8q21.3	rs12543318	88868340	<i>DCAF4L2</i>	A/C	0.32	0.38	2.43E-07	0.78 (0.72-0.84)	0.33	0.37	7.83E-04	0.86 (0.78-0.94)	8.80E-12	0.81	0.2050
8q21.3	rs1034832	88918331	<i>DCAF4L2</i>	C/A	0.31	0.36	5.92E-07	0.79 (0.73-0.85)	0.32	0.35	1.65E-03	0.86 (0.79-0.95)	1.35E-10	0.82	0.2243
8q24.21	rs7845615	129888794	<i>MYC</i>	A/G	0.22	0.18	5.11E-06	1.28 (1.17-1.41)	0.20	0.17	8.59E-05	1.25 (1.12-1.39)	1.03E-10	1.27	0.8110
8q24.21	rs7017252	129950844	<i>MYC</i>	A/G	0.08	0.05	3.27E-06	1.59 (1.36-1.85)	0.07	0.05	4.18E-08	1.62 (1.36-1.93)	8.47E-16	1.60	0.8960
9q22.2	rs7871395	92209587	<i>GADD45G</i>	A/G	0.30	0.26	4.54E-05	1.23 (1.13-1.34)	0.29	0.26	1.07E-03	1.17 (1.07-1.29)	6.06E-09	1.21	0.5782
9q22.33	rs7043516	100617433	<i>FOXE1</i>	C/A	0.04	0.06	1.68E-04	0.70 (0.59-0.85)	NA	NA	NA	NA	NA	NA	NA

10q25.3	rs6585429	118893231	<i>VAX1</i>	G/A	0.39	0.44	4.92E-08	0.81 (0.75-0.87)	0.39	0.45	2.22E-06	0.81 (0.74-0.88)	7.14E-13	0.81	0.9967
13q31.1	rs9545308	80639405	<i>SPRY2</i>	A/C	0.15	0.12	4.09E-05	1.30 (1.17-1.45)	0.14	0.11	2.34E-04	1.27 (1.12-1.44)	2.00E-09	1.29	0.8103
15q13.3	rs1258763	33050423	<i>GREM1</i>	A/G	0.08	0.07	2.21E-02	1.18 (1.02-1.37)	NA	NA	NA	NA	NA	NA	NA
15q22.2	rs78512626	61432877	<i>TPM1</i>	C/A	0.12	0.15	8.05E-06	0.76 (0.67-0.85)	0.14	0.15	3.84E-01	0.95 (0.84-1.07)	7.02E-05	0.84	0.0261
16p13.3	rs2283487	3969886	<i>CREBBP / ADCY9</i>	G/A	0.42	0.47	3.18E-06	0.83 (0.76-0.89)	0.43	0.47	3.91E-05	0.83 (0.76-0.91)	1.27E-10	0.83	0.9121
16p13.3	rs17136624	3996282	<i>CREBBP / ADCY9</i>	A/G	0.25	0.22	8.43E-05	1.21 (1.11-1.32)	0.27	0.23	3.11E-06	1.28 (1.15-1.42)	3.82E-10	1.24	0.5269
17p13.1	rs2872615	8914693	<i>NTNI</i>	G/A	0.43	0.48	7.45E-06	0.80 (0.74-0.87)	0.43	0.47	1.06E-04	0.84 (0.77-0.92)	8.81E-12	0.82	0.5224
17p13.1	rs1880646	8929845	<i>NTNI</i>	A/G	0.52	0.46	4.98E-06	1.25 (1.16-1.35)	0.52	0.48	2.60E-04	1.17 (1.08-1.28)	1.69E-11	1.22	0.4104
17q22	rs12951993	54760614	<i>NOG</i>	A/G	0.36	0.32	1.19E-05	1.21 (1.12-1.31)	0.36	0.33	2.88E-02	1.11 (1.01-1.21)	5.26E-07	1.16	0.2119
17q22	rs227731	54773238	<i>NOG</i>	C/A	0.36	0.32	1.74E-05	1.22 (1.12-1.32)	0.36	0.32	1.19E-03	1.16 (1.06-1.27)	8.83E-09	1.19	0.5623
17q23.2	rs16946713	61087073	<i>TANC2 / DCAF7</i>	G/A	0.07	0.06	5.94E-02	1.16 (0.99-1.35)	NA	NA	NA	NA	NA	NA	NA
17q25.3	rs2273280	76103663	<i>RBFOX3</i>	A/G	0.15	0.18	5.05E-05	0.79 (0.71-0.88)	NA	NA	NA	NA	NA	NA	NA
17q25.3	rs76579845	76598716	<i>RBFOX3</i>	A/C	0.02	0.04	2.08E-07	0.51 (0.40-0.65)	NA	NA	NA	NA	NA	NA	NA
19q13.11	rs10404307	33512011	<i>RHPN2</i>	C/A	0.15	0.18	8.99E-06	0.79 (0.71-0.88)	NA	NA	NA	NA	NA	NA	NA
20q12	rs6129653	39275603	<i>MAFB</i>	A/G	0.35	0.31	2.99E-06	1.21 (1.12-1.31)	0.35	0.30	5.78E-07	1.26 (1.15-1.39)	8.57E-12	1.23	0.5970

F_A: minor allele frequency in cases; F_U: minor allele frequency in controls; OR: odds ratio.

Alleles: shown as minor allele/major allele.

NSCLP Replication: replication study in 1,346 NSCLP cases and 4,542 controls of Chinese.

Meta analysis: Meta analysis of GWAS and NSCLP Replication.

The P value of GWAS and NSCLP Replication using using logistic regression test

P(F) (The P value using Cochran-Mantel-Haenszel test) and OR(F) were calculated using fixed model.

*P het: P value for heterozygosity using logistic regression test Bonferroni correction. P het > 0.05 was considered to signify no heterogeneity.

Supplementary Table 5. Independent Secondary signals observed in the discovery and NSCLP Replication samples when performing conditional on one previously reported loci.

Loci	Gene	SNP	Alleles	Combined Discovery and Replication 1					Logistic condition			LD	
				MAF		P	OR	95% CI	Condition	P	OR	D'	r ²
				Cases	Controls								
1q32.2	<i>IRF6</i>	rs861020	A/G	0.23	0.19	1.30E-14	1.31	(1.23-1.41)	rs642961	NA	NA	0.99	0.98
									rs2064163	1.64E-06	1.20	0.82	0.12
									rs9430019	8.79E-17	1.34	0.24	0.01
	<i>IRF6/DIEXF</i>	rs642961	A/G	0.23	0.19	2.76E-15	1.32	(1.23-1.41)	rs861020	NA	NA	0.99	0.98
									rs2064163	9.80E-07	1.20	0.82	0.12
									rs9430019	1.81E-17	1.35	0.25	0.01
	<i>DIEXF/SYT14</i>	rs2064163	A/C	0.38	0.44	8.60E-19	0.77	(0.73-0.82)	rs861020	6.43E-11	0.81	0.82	0.12
									rs642961	1.05E-10	0.82	0.82	0.12
									rs9430019	1.43E-09	0.81	1.00	0.28
	<i>DIEXF/SYT14</i>	rs9430019	A/G	0.31	0.26	1.68E-12	1.25	(1.18-1.34)	rs861020	5.64E-15	1.28	0.24	0.01
									rs642961	1.06E-14	1.28	0.25	0.01
									rs2064163	4.51E-03	1.11	1.00	0.28

MAF: minor allele frequency; OR: odds ratio; 95%CI: 95% confidence interval; LD: linkage disequilibrium; D': D prime; r²: r square.

Alleles: shown as minor allele/major allele.

P value using stepwise subset-based conditional logistic regression

Supplementary Table 6. Association results for 40 SNPs in NSCLO Replication.

Loci	SNP	BP (hg19)	Alleles	NSCLO Replication				New/Reported
				F_A	F_U	P	OR	
2p25.1	rs287980	9971366	G/A	0.25	0.26	2.34E-01	0.93 (0.84-1.05)	New
2p25.1	rs287982	9972442	G/A	0.25	0.26	1.65E-01	0.92 (0.83-1.03)	New
4p16.2	rs34246903	4794195	C/A	0.40	0.42	2.91E-01	0.95 (0.86-1.05)	New
4p16.2	rs1907989	4818925	A/G	0.48	0.50	6.42E-02	0.91 (0.83-1.01)	New
4q28.1	rs908822	124906257	A/G	0.09	0.08	7.64E-02	1.17 (0.98-1.38)	New
5p12	rs10462065	44068846	A/C	0.24	0.22	7.92E-02	1.11 (0.99-1.24)	New
6p24.3	rs9381107	9469238	A/G	0.32	0.35	4.79E-02	0.90 (0.81-1.00)	New
8p11.23	rs13317	38269514	G/A	0.31	0.33	7.59E-02	0.91 (0.82-1.01)	New
8q22.1	rs12681366	95401265	G/A	0.46	0.48	6.16E-02	0.91 (0.83-1.01)	New
8q22.1	rs957448	95541302	G/A	0.47	0.49	5.72E-02	0.91 (0.83-1.00)	New
9q22.32	rs10512248	98259703	C/A	0.33	0.35	4.47E-02	0.90 (0.81-1.00)	New
12q13.13	rs3741442	53346750	G/A	0.44	0.42	6.42E-02	1.10 (0.99-1.21)	New
12q13.2	rs705704	56435412	A/G	0.24	0.25	2.84E-01	0.94 (0.84-1.05)	New
12q21.1	rs2304269	72080272	G/A	0.41	0.44	2.04E-02	0.89 (0.81-0.98)	New
12q21.1	rs7967428	72089040	G/A	0.41	0.44	6.56E-02	0.91 (0.83-1.01)	New
14q22.1	rs7148069	51839645	A/G	0.21	0.20	6.21E-01	1.03 (0.91-1.16)	New
14q32.13	rs1243572	95379499	G/A	0.47	0.43	7.75E-04	1.18 (1.07-1.30)	New
14q32.13	rs1243573	95379583	C/A	0.46	0.43	8.19E-03	1.14 (1.03-1.26)	New
17q21.32	rs4968247	44988703	A/G	0.37	0.40	1.44E-03	0.85 (0.77-0.94)	New
17q21.32	rs1838105	45008935	A/G	0.43	0.38	5.98E-04	1.19 (1.08-1.31)	New
1p22.1	rs4147803	94582293	G/C	0.30	0.34	9.89E-04	0.84 (0.75-0.93)	Reported
1q32.2	rs861020	209977111	A/G	0.30	0.18	1.02E-28	1.86 (1.67-2.08)	Reported

1q32.2	rs642961	209989270	A/G	0.30	0.18	1.69E-30	1.90 (1.70-2.13)	Reported
1q32.2	rs2064163	210048819	A/C	0.39	0.45	1.06E-06	0.78 (0.71-0.86)	Reported
1q32.2	rs9430019	210050794	A/G	0.30	0.26	2.28E-04	1.22 (1.10-1.36)	Reported
2p24.2	rs10172734	16733054	G/A	0.25	0.34	1.69E-14	0.65 (0.58-0.73)	Reported
2p24.2	rs7552	16733928	A/G	0.26	0.32	1.62E-07	0.75 (0.67-0.83)	Reported
8q21.3	rs12543318	88868340	A/C	0.31	0.37	1.84E-07	0.76 (0.68-0.84)	Reported
8q21.3	rs1034832	88918331	C/A	0.28	0.34	1.05E-07	0.75 (0.67-0.83)	Reported
8q24.21	rs7845615	129888794	A/G	0.21	0.18	8.40E-03	1.18 (1.04-1.33)	Reported
8q24.21	rs7017252	129950844	A/G	0.07	0.05	2.88E-03	1.36 (1.11-1.66)	Reported
9q22.2	rs7871395	92209587	A/G	0.31	0.27	1.22E-04	1.23 (1.11-1.37)	Reported
10q25.3	rs6585429	118893231	G/A	0.38	0.44	8.42E-07	0.78 (0.71-0.86)	Reported
13q31.1	rs9545308	80639405	A/C	0.14	0.12	4.95E-03	1.23 (1.06-1.42)	Reported
16p13.3	rs2283487	3969886	G/A	0.45	0.47	1.47E-01	0.93 (0.84-1.03)	Reported
16p13.3	rs17136624	3996282	A/G	0.24	0.22	1.54E-01	1.09 (0.97-1.22)	Reported
17p13.1	rs2872615	8914693	G/A	0.43	0.47	8.21E-04	0.85 (0.77-0.93)	Reported
17p13.1	rs1880646	8929845	A/G	0.51	0.49	6.30E-02	1.10 (1.00-1.21)	Reported
17q22	rs227731	54773238	C/A	0.36	0.34	2.98E-02	1.12 (1.01-1.24)	Reported
20q12	rs6129653	39275603	A/G	0.34	0.28	2.34E-06	1.28 (1.16-1.42)	Reported

F_A: minor allele frequency in cases; F_U: minor allele frequency in controls; OR: odds ratio.

Alleles: shown as minor allele/major allele.

NSCLO Replication: replication study in 1,104 NSCLO cases and 3,312 controls of Chinese.

P value using logistic regression test

Supplementary Table 7. Association results of 40 SNPs in NSCPO Replication.

Loci	SNP	BP (hg19)	Alleles	NSCPO Replication				New/Reported
				F_A	F_U	P	OR	
2p25.1	rs287980	9971366	G/A	0.27	0.26	7.87E-01	1.02 (0.91-1.13)	New
2p25.1	rs287982	9972442	C/T	0.27	0.26	7.63E-01	1.02 (0.91-1.14)	New
4p16.2	rs34246903	4794195	C/A	0.41	0.42	7.77E-01	0.99 (0.89-1.09)	New
4p16.2	rs1907989	4818925	G/A	0.50	0.50	5.78E-01	1.03 (0.93-1.13)	New
4q28.1	rs908822	124906257	T/C	0.09	0.08	5.21E-01	1.06 (0.89-1.26)	New
5p12	rs10462065	44068846	A/C	0.22	0.22	7.17E-01	0.98 (0.87-1.10)	New
6p24.3	rs9381107	9469238	A/G	0.34	0.35	2.81E-01	0.95 (0.85-1.05)	New
8p11.23	rs13317	38269514	C/T	0.32	0.33	3.83E-01	0.95 (0.86-1.06)	New
8q22.1	rs12681366	95401265	C/T	0.47	0.48	4.01E-01	0.96 (0.87-1.06)	New
8q22.1	rs957448	95541302	G/A	0.48	0.49	1.33E-01	0.93 (0.84-1.02)	New
9q22.32	rs10512248	98259703	G/T	0.31	0.35	1.23E-04	0.82 (0.73-0.91)	New
12q13.13	rs3741442	53346750	C/T	0.44	0.42	9.72E-02	1.09 (0.99-1.20)	New
12q13.2	rs705704	56435412	A/G	0.25	0.25	1.00E+00	1.00 (0.89-1.12)	New
12q21.1	rs2304269	72080272	C/T	0.45	0.44	3.03E-01	1.05 (0.95-1.16)	New
12q21.1	rs7967428	72089040	G/A	0.45	0.44	1.72E-01	1.07 (0.97-1.18)	New
14q22.1	rs7148069	51839645	T/C	0.19	0.20	4.90E-01	0.96 (0.85-1.08)	New
14q32.13	rs1243572	95379499	C/T	0.44	0.43	2.14E-01	1.06 (0.96-1.17)	New
14q32.13	rs1243573	95379583	C/A	0.45	0.43	8.60E-02	1.09 (0.99-1.20)	New
17q21.32	rs4968247	44988703	T/C	0.40	0.40	4.34E-01	0.96 (0.87-1.06)	New
17q21.32	rs1838105	45008935	A/G	0.38	0.38	9.30E-01	1.00 (0.90-1.10)	New
1p22.1	rs4147803	94582293	C/G	0.32	0.34	2.72E-01	0.94 (0.85-1.05)	Reported
1q32.2	rs861020	209977111	A/G	0.17	0.18	6.63E-02	0.89 (0.78-1.01)	Reported

1q32.2	rs642961	209989270	A/G	0.17	0.18	1.16E-01	0.90 (0.79-1.03)	Reported
1q32.2	rs2064163	210048819	T/G	0.44	0.45	8.25E-01	0.99 (0.90-1.09)	Reported
1q32.2	rs9430019	210050794	T/C	0.19	0.26	1.58E-11	0.66 (0.59-0.75)	Reported
2p24.2	rs10172734	16733054	G/A	0.33	0.34	4.36E-01	0.96 (0.87-1.06)	Reported
2p24.2	rs7552	16733928	A/G	0.28	0.32	1.81E-03	0.84 (0.76-0.94)	Reported
8q21.3	rs12543318	88868340	A/C	0.35	0.37	1.18E-01	0.92 (0.83-1.02)	Reported
8q21.3	rs1034832	88918331	G/T	0.35	0.34	5.45E-01	1.03 (0.93-1.14)	Reported
8q24.21	rs7845615	129888794	T/C	0.19	0.18	3.06E-01	1.07 (0.94-1.21)	Reported
8q24.21	rs7017252	129950844	T/C	0.07	0.05	4.49E-04	1.43 (1.17-1.74)	Reported
9q22.2	rs7871395	92209587	T/C	0.27	0.27	6.28E-01	1.03 (0.92-1.15)	Reported
10q25.3	rs6585429	118893231	G/A	0.43	0.44	2.96E-01	0.95 (0.86-1.05)	Reported
13q31.1	rs9545308	80639405	T/G	0.14	0.12	7.49E-03	1.22 (1.05-1.40)	Reported
16p13.3	rs2283487	3969886	G/A	0.47	0.47	9.49E-01	1.00 (0.90-1.10)	Reported
16p13.3	rs17136624	3996282	A/G	0.22	0.22	6.91E-01	1.02 (0.91-1.15)	Reported
17p13.1	rs2872615	8914693	C/T	0.49	0.47	5.82E-02	1.10 (1.00-1.21)	Reported
17p13.1	rs1880646	8929845	A/G	0.47	0.49	2.52E-01	0.94 (0.86-1.04)	Reported
17q22	rs227731	54773238	G/T	0.33	0.34	4.40E-01	0.96 (0.87-1.06)	Reported
20q12	rs6129653	39275603	T/C	0.31	0.28	8.99E-03	1.15 (1.04-1.28)	Reported

F_A: minor allele frequency in cases; F_U: minor allele frequency in controls; OR: odds ratio.

Alleles: shown as minor allele/major allele.

NSCPO Replication: replication study in 1,104 NSCPO cases and 3,312 controls of Chinese.

The P value using logistic regression test;

Supplementary Table 8. Genotype-phenotype analysis.

	Loci	SNP	BP (hg19)	Allele	F_A	F_U	F-Healthy*	P	OR[#]	Gene
Gender (NSCLP)	1q32.2	rs861020	209977111	A/G	0.25	0.20	0.19	2.94E-04	1.27 (1.12-1.45)	<i>IRF6</i>
		rs642961	209989270	A/G	0.25	0.20	0.19	3.47E-04	1.27 (1.11-1.44)	<i>IRF6</i>
		rs2064163	210048819	A/C	0.36	0.41	0.44	1.38E-04	1.23 (1.11-1.37)	<i>IRF6</i>
		rs9430019	210050794	A/G	0.32	0.28	0.26	1.26E-03	1.21 (1.08-1.36)	<i>IRF6</i>
Mother's Age (NSCLP)	8q21.3	rs12543318	88868340	A/C	0.27	0.34	0.38	3.29E-04	1.43 (1.18-1.72)	<i>MMP16</i>
		rs1034832	88918331	C/A	0.26	0.32	0.36	2.98E-03	1.35 (1.11-1.64)	<i>MMP16</i>

NSCLP: non-syndromic cleft lip with palate; OR: odds ratio.

F_A: minor allele frequency of male or older mothers (> 35y) in NSCLP, respectively.

F_U: minor allele frequency of female or standard age mothers in the reference group (25 - 35y) in NSCLP, respectively.

Alleles: shown as minor allele/major allele, and risk allele was in bold.

[#]OR was calculated based on risk allele.

*Minor allele frequency in controls from discovery GWAS stage.

The P value using logistic regression test;

Supplementary Table 9. Association results for 24 SNPs in foreign replication data sets.

Loci	SNP	BP	Central European replication					Asian case-parent trios for replication							European ancestry case-parent trios for replication							New /Reported		
			Alleles	F_A	F_U	OR	P	MAF	Beta coef	SE	Test stat	RR	Trios	P	Missing	MAF	Beta coef	SE	Test stat	RR	Trios		P	Missing
2p25.1	rs287980	9971366	G/A	0.20	0.21	0.94	5.34E-01	0.26	-0.06	0.08	0.54	0.94	544	4.63E-01	0.00	0.21	-0.03	0.10	0.09	0.97	324	7.62E-01	0.00	New
2p25.1	rs287982	9972442	C/T	0.20	0.21	0.94	5.21E-01	0.26	-0.06	0.08	0.54	0.94	544	4.63E-01	0.00	0.21	-0.04	0.10	0.16	0.96	321	6.85E-01	0.00	New
4p16.2	rs34246903	4794195	A/C	0.70	0.66	1.22	2.39E-02	0.42	-0.16	0.07	4.99	0.85	604	2.54E-02	0.02	0.33	0.12	0.09	1.92	1.13	397	1.65E-01	0.01	New
4p16.2	rs1907989	4818925	A/G	0.57	0.61	0.83	1.92E-02	0.49	0.20	0.07	8.33	1.22	646	3.91E-03	0.00	0.36	0.06	0.09	0.43	1.06	423	5.14E-01	0.00	New
4q28.1	rs908822	124906257	C/T	0.92	0.93	0.83	2.44E-01	0.08	0.34	0.13	7.24	1.41	230	7.14E-03	0.00	0.07	0.14	0.16	0.77	1.15	144	3.80E-01	0.00	New
5p12	rs10462065	44068846	C/A	0.89	0.89	1.05	7.28E-01	0.24	0.18	0.08	4.71	1.19	510	3.01E-02	0.01	0.12	0.05	0.12	0.19	1.05	237	6.66E-01	0.00	New
6p24.3	rs9381107	9469238	G/A	0.84	0.82	1.18	1.43E-01	0.32	0.02	0.08	0.04	1.02	503	8.43E-01	0.05	0.15	-0.03	0.11	0.08	0.97	271	7.75E-01	0.00	New
8p11.23	rs13317	38269514	T/C	0.79	0.78	1.08	4.46E-01	0.31	-0.08	0.07	1.24	0.92	582	2.65E-01	0.00	0.23	-0.28	0.09	8.70	0.76	377	3.17E-03	0.00	New
8q22.1	rs12681366	95401265	T/C	0.68	0.66	1.09	3.01E-01	0.45	-0.04	0.07	0.34	0.96	639	5.62E-01	0.00	0.31	-0.11	0.09	1.45	0.90	381	2.28E-01	0.00	New
8q22.1	rs957448	95541302	A/G	0.77	0.74	1.14	1.49E-01	0.47	-0.11	0.07	2.44	0.90	647	1.18E-01	0.00	0.23	-0.08	0.10	0.69	0.92	348	4.07E-01	0.00	New
9q22.32	rs10512248	98259703	T/G	0.66	0.67	0.93	4.34E-01	0.28	-0.21	0.09	6.03	0.81	441	1.41E-02	0.09	0.32	-0.15	0.09	2.71	0.86	381	1.00E-01	0.02	New
12q13.13	rs3741442	53346750	C/T	0.99	1.00	0.72	5.42E-01	0.54	-0.26	0.07	14.64	0.77	630	1.30E-04	0.01	0.02	-0.73	0.33	5.01	0.48	38	2.52E-02	0.00	New
12q13.2	rs705704	56435412	G/A	0.66	0.69	0.86	7.44E-02	0.23	0.03	0.08	0.19	1.04	516	6.61E-01	0.00	0.35	0.28	0.09	10.58	1.32	439	1.15E-03	0.00	New
12q21.1	rs2304269	72080272	T/C	0.95	0.95	1.05	7.81E-01	0.43	-0.16	0.07	4.92	0.85	564	2.66E-02	0.04	0.07	-0.08	0.17	0.25	0.92	135	6.17E-01	0.00	New
12q21.1	rs7967428	72089040	A/G	0.95	0.95	1.00	9.91E-01	0.43	-0.16	0.07	5.15	0.85	630	2.32E-02	0.00	0.07	-0.07	0.17	0.17	0.93	136	6.78E-01	0.00	New
14q22.1	rs1748069	51839645	C/T	0.68	0.67	1.02	7.92E-01	0.17	0.02	0.10	0.02	1.02	306	8.75E-01	0.07	0.31	0.10	0.10	1.05	1.11	336	3.06E-01	0.04	New
14q32.13	rs1243572	95379499	T/C	0.21	0.22	0.91	3.65E-01	0.57	-0.02	0.07	0.07	0.98	656	7.84E-01	0.00	0.23	-0.07	0.10	0.46	0.94	355	4.99E-01	0.00	New
14q32.13	rs1243573	95379583	A/C	0.20	0.22	0.92	4.10E-01	0.57	-0.02	0.07	0.07	0.98	656	7.84E-01	0.00	0.23	-0.07	0.10	0.46	0.94	355	4.99E-01	0.00	New
17q21.32	rs4968247	44988703	C/T	0.34	0.33	1.07	4.81E-01	0.61	0.23	0.08	9.13	1.26	528	2.52E-03	0.05	0.33	0.14	0.09	2.40	1.15	372	1.21E-01	0.03	New

17q21.32	rs1838105	45008935	A/G	0.39	0.33	1.27	5.83E-03	0.40	0.17	0.07	6.00	1.19	625	1.43E-02	0.00	0.38	0.12	0.08	2.22	1.13	449	1.37E-01	0.00	New
2p24.2	rs10172734	16733054	G/A	0.68	0.72	0.82	2.42E-02	0.29	-0.14	0.08	3.59	0.87	555	5.83E-02	0.01	0.66	-0.20	0.09	5.49	0.82	423	1.91E-02	0.00	Reported
2p24.2	rs7552	16733928	A/G	0.68	0.72	0.82	2.52E-02	0.27	-0.15	0.08	3.55	0.86	546	5.95E-02	0.01	0.66	-0.20	0.09	5.28	0.82	424	2.15E-02	0.00	Reported
16p13.3	rs2283487	3969886	A/G	0.38	0.35	1.13	1.49E-01	0.55	0.10	0.07	1.95	1.10	614	1.62E-01	0.01	0.36	0.22	0.08	6.92	1.25	440	8.51E-03	0.00	Reported
16p13.3	rs17136624	3996282	G/A	0.70	0.73	0.87	1.19E-01	0.22	0.08	0.08	0.83	1.08	480	3.61E-01	0.00	0.28	0.09	0.09	0.90	1.09	397	3.43E-01	0.00	Reported

Central European Replication: replication study in 399 NSCL/P cases and 1,318 controls of Central European origin.

Asian case-parent trios for replication: replication study in 861 NSCL/P case-parent trios of Asian ancestry (including: Chinese, Singaporean, Taiwanese, Korean and Filipino).

European ancestry case-parent trios for replication: replication study in 557 NSCL/P case-parent trios of European ancestry.

The P value using logistic regression test;

Supplementary Table 10. Comparisons of the allele frequencies for 9 previously reported SNPs obtained from the 22 reported loci among different populations based on GWAS data.

Loci	Index SNPs	Alleles	MAF_cases	MAF_controls	Population	Types
1p22.1	rs481931	A	0.339	/	Asian & European	trios
			0.351	/	European	trios
			0.332	/	Asian	trios
		A/C	0.33	0.37	Chinese Han	case-control
	rs560426	G	0.399	/	Asian & European	trios
			0.471	/	European	trios
		0.342	/	Asian	trios	
	G/A	0.32	0.3	Chinese Han	case-control	
1q32.2	rs861020	A	0.245	/	Asian & European	trios
			0.246	/	European	trios
			0.244	/	Asian	trios
		A/G	0.24	0.19	Chinese Han	case-control
	rs642961	A/G	0.26	/	Norway	trios
			0.24	/	Denmark	trios
			0.25	/	EUROCRAN	trios
			0.24	/	Europe	trios
		0.32	/	Philippines	trios	
	A/G	0.24	0.19	Chinese Han	case-control	

8q24.21	rs987525	A/C	0.381(A)	0.202(A)	Central European	case-control
		A/C	0.07	0.07	Chinese Han	case-control
	rs1530300	C/T	0.478(C)	0.301(C)	Central European	case-control
		G/A	0.05	0.04	Chinese Han	case-control
	rs7017252	T/C	0.449(C)	0.393(T)	Central European	case-control
		A/G	0.08	0.05	Chinese Han	case-control
15q13.3	rs1258763	G/A	0.252 (nsCLP_hard+soft)	/	European, Asian, Central European, Mexican, Yemeni	Meta (including trios)
			0.119 (nsCLP_soft)	/	European, Asian, Central European, Mexican, Yemeni	Meta (including trios)
		A/G	0.08	0.07	Chinese Han	case-control
17q22	rs227731	C/A	0.496 (A)	0.416 (C)	Central European	case-control
		C/A	0.36	0.32	Chinese Han	case-control

Supplementary Table 11. Expression results for candidate genes identified in GWAS on mouse embryo drawn from EMAGE database.

Gene	Chr.	Symbol	ID	Structures	Level	Theiler Stage	Stage Given	EMAGE ID
branchial arch								
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	1st branchial arch mandibular component	weak	TS17	10.5 dpc	EMAGE:26246
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	1st branchial arch maxillary component	weak	TS17	10.5 dpc	EMAGE:26246
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	2nd branchial arch	weak	TS17	10.5 dpc	EMAGE:26246
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch	strong	TS15	9.5 dpc	EMAGE:3839
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component	moderate	TS15	9.5 dpc	EMAGE:5411
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component	moderate	TS15	9.5 dpc	EMAGE:5411
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component	weak	TS15	9.5 dpc	EMAGE:24726
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	2nd branchial arch	weak	TS15	9.5 dpc	EMAGE:3839
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	2nd branchial arch mesenchyme	moderate	TS15	9.5 dpc	EMAGE:5411
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	3rd branchial arch	weak	TS15	9.5 dpc	EMAGE:3839
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component	moderate	TS17	10.5dpc	EMAGE:5290
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component	weak	TS17	10.5 dpc	EMAGE:26194
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component	weak	TS17	10.5 dpc	EMAGE:26194
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component mesenchyme	strong	TS18	10.5 dpc	EMAGE:653
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component mesenchyme	strong	TS18	10.5 dpc	EMAGE:653
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component mesenchyme	strong	TS18	10.5 dpc	EMAGE:3277
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component ectoderm	strong	TS17	10.5dpc	EMAGE:5290

<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	2nd branchial arch	weak	TS17	10.5 dpc	EMAGE:26194
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	branchial arch	strong	TS18	10.5 dpc	EMAGE:3518
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component mesenchyme	moderate	TS18	11 dpc	EMAGE:493
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component mesenchyme	moderate	TS18	11 dpc	EMAGE:493
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component mesenchyme	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component mesenchyme	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mandibular component mesenchyme derived from neural crest	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch maxillary component mesenchyme derived from neural crest	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial groove	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	2nd branchial arch mesenchyme derived from neural crest	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	2nd branchial arch	strong	TS19	11.5 dpc	EMAGE:27695
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	2nd branchial arch mesenchyme	detected	TS19	11.5 dpc	EMAGE:3278
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	3rd branchial arch mesenchyme	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	3rd branchial arch mesenchyme derived from neural crest	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	4th branchial arch mesenchyme derived from neural crest	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	1st branchial arch mesenchyme derived from neural crest	strong	TS14	17 Somite no.	EMAGE:628
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	2nd branchial arch mesenchyme derived from neural crest	strong	TS14	17 Somite no.	EMAGE:628
<i>SPRY1</i>	4	<i>Spry1</i>	MGI:1345139	1st branchial arch mandibular component mesenchyme	-	TS17	10.5 dpc	EMAGE:3624
<i>SPRY1</i>	4	<i>Spry1</i>	MGI:1345139	1st branchial arch maxillary component mesenchyme	-	TS17	10.5 dpc	EMAGE:3624
<i>CDK2</i>	12	<i>Cdk2</i>	MGI:104772	1st branchial arch maxillary component	strong	TS15	9.5 dpc	EMAGE:25561
<i>CDK2</i>	12	<i>Cdk2</i>	MGI:104772	1st branchial arch mandibular component	strong	TS15	9.5 dpc	EMAGE:25561
<i>CDK2</i>	12	<i>Cdk2</i>	MGI:104772	2nd branchial arch	strong	TS15	9.5 dpc	EMAGE:25561
<i>CDK2</i>	12	<i>Cdk2</i>	MGI:104772	1st branchial arch mandibular component	strong	TS17	10.5 dpc	EMAGE:27046
<i>CDK2</i>	12	<i>Cdk2</i>	MGI:104772	1st branchial arch maxillary component	strong	TS17	10.5 dpc	EMAGE:27046
<i>ERBB3</i>	12	<i>ErbB3</i>	MGI:95411	branchial arch	detected	TS16	10.5 dpc	EMAGE:5299

<i>ERBB3</i>	12	<i>ErbB3</i>	MGI:95411	3rd branchial arch mesenchyme derived from neural crest	detected	TS16	10.5 dpc	EMAGE:5299
<i>ERBB3</i>	12	<i>ErbB3</i>	MGI:95411	4th branchial arch mesenchyme derived from neural crest	detected	TS16	10.5 dpc	EMAGE:5299
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	1st branchial arch mandibular component mesenchyme	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	1st branchial arch maxillary component mesenchyme	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	1st branchial groove ectoderm	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	1st branchial pouch	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	2nd branchial arch	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	2nd branchial groove ectoderm	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	2nd branchial pouch	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	3rd branchial arch	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	3rd branchial groove ectoderm	detected	TS15	9.75 dpc	EMAGE:4618
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	3rd branchial pouch	detected	TS15	9.75 dpc	EMAGE:4618
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	1st branchial arch	detected	TS17	10.5 dpc	EMAGE:732
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	1st branchial arch	detected	TS17	10.5 dpc	EMAGE:3973
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	1st branchial arch mandibular component	strong	TS17	10.5 dpc	EMAGE:26593
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	1st branchial arch maxillary component	strong	TS17	10.5 dpc	EMAGE:26593
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	2nd branchial arch	detected	TS17	10.5 dpc	EMAGE:732
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	2nd branchial arch	detected	TS17	10.5 dpc	EMAGE:3973
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	2nd branchial arch	strong	TS17	10.5 dpc	EMAGE:26593
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	branchial arch	strong	TS17	10.5 dpc	EMAGE:732
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	1st branchial groove	strong	TS19	11.5 dpc	EMAGE:5405
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	2nd branchial arch	strong	TS19	11.5 dpc	EMAGE:28094
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	1st branchial arch maxillary component	strong	TS17	10.5 dpc	EMAGE:4987
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	1st branchial arch maxillary component	strong	TS18	10.5 dpc	EMAGE:5279
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	1st branchial arch mandibular component	strong	TS17	10.5 dpc	EMAGE:4987
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	1st branchial arch mandibular component ectoderm	strong	TS18	10.5 dpc	EMAGE:5279

<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	2nd branchial arch	strong	TS17	10.5 dpc	EMAGE:4987
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	3rd branchial arch	strong	TS17	10.5 dpc	EMAGE:4987
<i>MAFB</i>	20	<i>Mafb</i>	MGI:1914981	1st branchial arch maxillary component	strong	TS17	10.5 dpc	EMAGE:26188
maxilla								
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	maxillary process	strong	TS19	11.5 dpc	EMAGE:27747
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	maxillary process	strong	TS19	11.5 dpc	EMAGE:27695
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	maxillary process	detected	TS19	11.5 dpc	EMAGE:3278
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	maxillary process	strong	TS19	11.5 dpc	EMAGE:5405
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	maxillary process	strong	TS19	11.5 dpc	EMAGE:28094
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	maxillary process epithelium	strong	TS20	12.5 dpc	EMAGE:5390
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	maxillary process	strong	TS19	11.5 dpc	EMAGE:4989
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	maxillary process	moderate	TS20	12.5 dpc	EMAGE:4984
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	maxillary process epithelium	moderate	TS20	12.5 dpc	EMAGE:4984
<i>MAFB</i>	20	<i>Mafb</i>	MGI:1914981	maxillary process	strong	TS19	11.5 dpc	EMAGE:27689
mandible								
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	lower jaw molar	strong	TS23	14.5 dpc	EMAGE:6816
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	mandibular process	strong	TS19	11.5 dpc	EMAGE:27695
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	mandibular process	moderate	TS19	11.5 dpc	EMAGE:5291
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	mandibular process mesenchyme	detected	TS19	11.5 dpc	EMAGE:3278
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	lower jaw incisor	moderate	TS23	14.5 dpc	EMAGE:11923
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	lower jaw molar	moderate	TS23	14.5 dpc	EMAGE:11923
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	mandibular process	strong	TS19	11.5 dpc	EMAGE:5405
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	mandibular process	strong	TS19	11.5 dpc	EMAGE:28094
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	mandibular process	strong	TS19	11.5 dpc	EMAGE:4989

lip

<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	rest of upper lip	strong	TS21	13.5 dpc	EMAGE:5413
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	rest of upper lip	strong	TS22	-	EMAGE:5414
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	upper lip	moderate	TS21	13.5 dpc	EMAGE:4985
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	upper lip	strong	TS22	14.5 dpc	EMAGE:4986
<i>MAFB</i>	20	<i>Mafb</i>	MGI:1914981	lower lip	moderate	TS23	14.5 dpc	EMAGE:19184

palate

<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	palatal shelf epithelium	moderate	TS23	14.5 dpc	EMAGE:11923
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	palatal shelf	strong	TS20	12.5 dpc	EMAGE:5390
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	palatal shelf	weak	TS21	13.5 dpc	EMAGE:5391
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	primary palate epithelium	weak	TS20	12.5 dpc	EMAGE:4984
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	palatal shelf epithelium	weak	TS21	13.5 dpc	EMAGE:4985

oral

<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	oral epithelium	strong	TS23	14.5 dpc	EMAGE:6816
<i>VAX1</i>	10	<i>Vax1</i>	MGI:1277163	oral region epithelium	detected	TS17	12.5 dpc	EMAGE:542
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	oral epithelium	moderate	TS23	14.5 dpc	EMAGE:11923
<i>KRT8</i>	12	<i>Krt8</i>	MGI:1921377	oral epithelium	moderate	TS23	14.5 dpc	EMAGE:10450

frontal process

<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	frontal process mesenchyme	-	TS18	11.5 dpc	EMAGE:158
-------------	---	-------------	-----------	----------------------------	---	------	----------	-----------

philtrum

<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	philtrum	weak	TS21	13.5 dpc	EMAGE:5413
-------------	---	-------------	-----------	----------	------	------	----------	------------

others

nose

<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	naris	strong	TS23	14.5 dpc	EMAGE:6816
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	nose	strong	TS20	12.5 dpc	EMAGE:5412
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	nose	-	TS18	11.5 dpc	EMAGE:158
<i>BAG4</i>	8	<i>Bag4</i>	MGI:1914634	naris	strong	TS23	14.5 dpc	EMAGE:10095
<i>VAX1</i>	10	<i>Vax1</i>	MGI:1277163	nose	detected	TS17	12.5 dpc	EMAGE:542
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	naris	strong	TS23	14.5 dpc	EMAGE:11923
<i>ERBB3</i>	12	<i>ErbB3</i>	MGI:95411	anterior naris epithelium	moderate	TS23	14.5 dpc	EMAGE:16072
<i>ERBB3</i>	12	<i>ErbB3</i>	MGI:95411	external naris epithelium	moderate	TS23	14.5 dpc	EMAGE:16072
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	nose	strong	TS22	14.5 dpc	EMAGE:4986

nasal

<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	fronto-nasal process	weak	TS15	9.5 dpc	EMAGE:3839
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	medial-nasal process	strong	TS18	10.5 dpc	EMAGE:653
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	medial-nasal process	strong	TS18	10.5 dpc	EMAGE:3277
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	medial-nasal process	strong	TS17	10.5dpc	EMAGE:5290
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	latero-nasal process	strong	TS18	10.5 dpc	EMAGE:653
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	latero-nasal process	strong	TS18	10.5 dpc	EMAGE:3277
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	latero-nasal process	strong	TS17	10.5dpc	EMAGE:5290
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	medial-nasal process mesenchyme	moderate	TS18	11 dpc	EMAGE:493
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	latero-nasal process mesenchyme	moderate	TS18	11 dpc	EMAGE:493
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	nasal epithelium	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	medial-nasal process	detected	TS19	11.5 dpc	EMAGE:3278
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	medial-nasal process	strong	TS19	11.5 dpc	EMAGE:5291
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	medial-nasal process mesenchyme	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	latero-nasal process	detected	TS19	11.5 dpc	EMAGE:3278

<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	latero-nasal process	strong	TS19	11.5 dpc	EMAGE:5291
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	latero-nasal process mesenchyme	-	TS18	11.5 dpc	EMAGE:158
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	nasal cavity epitheliumnasal cavity epithelium	detected	TS20	12.5 dpc	EMAGE:646
<i>SPRY1</i>	4	<i>Spry1</i>	MGI:1345139	fronto-nasal process	-	TS19	10.5 dpc	EMAGE:1252
<i>FGF10</i>	5	<i>Fgf10</i>	MGI:1099809	nasal epithelium	detected	TS17	10.5 dpc	EMAGE:3769
<i>VAX1</i>	10	<i>Vax1</i>	MGI:1277163	fronto-nasal process	detected	TS15	9.5 dpc	EMAGE:253
<i>VAX1</i>	10	<i>Vax1</i>	MGI:1277163	fronto-nasal process ectoderm	detected	TS15	9.5 dpc	EMAGE:253
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	fronto-nasal process	detected	TS18	10.5 dpc	EMAGE:4619
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	fronto-nasal process	detected	TS17	10.5 dpc	EMAGE:3973
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	medial-nasal process	strong	TS19	11.5 dpc	EMAGE:5405
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	latero-nasal process	strong	TS19	11.5 dpc	EMAGE:5405
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	medial-nasal process	strong	TS17	10.5 dpc	EMAGE:4987
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	medial-nasal process	strong	TS18	10.5 dpc	EMAGE:5279
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	latero-nasal process	strong	TS17	10.5 dpc	EMAGE:4987
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	latero-nasal process	strong	TS18	10.5 dpc	EMAGE:5279
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	medial-nasal process	weak	TS19	11.5 dpc	EMAGE:4989
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	latero-nasal process	moderate	TS19	11.5 dpc	EMAGE:4989
<i>NOG</i>	17	<i>Nog</i>	MGI:104327	nasal septum	weak	TS23	14.5 dpc	EMAGE:8431
maxilla								
<i>PTCH1</i>	9	<i>Ptch1</i>	MGI:105373	maxilla	moderate	TS23	14.5 dpc	EMAGE:16248
<i>PTCH1</i>	9	<i>Ptch1</i>	MGI:105373	maxilla	-	TS23	14.5 dpc	EMAGE:21444
<i>PTCH1</i>	9	<i>Ptch1</i>	MGI:105373	upper jaw	-	TS23	14.5 dpc	EMAGE:21444
mandible								
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	lower jaw molar	strong	TS23	14.5 dpc	EMAGE:6816
<i>MMP16</i>	8	<i>Mmp16</i>	MGI:1276107	mandible	moderate	TS23	14.5 dpc	EMAGE:7073

<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	mandible	moderate	TS23	14.5 dpc	EMAGE:16248	
<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	mandible	-	TS23	14.5 dpc	EMAGE:21444	
<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	lower jaw	-	TS23	14.5 dpc	EMAGE:21444	
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	lower jaw incisor	moderate	TS23	14.5 dpc	EMAGE:11923	
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	lower jaw molar	moderate	TS23	14.5 dpc	EMAGE:11923	
<i>NOG</i>	17	<i>Nog</i>	MGI:104327	mandible	weak	TS23	14.5 dpc	EMAGE:8431	
tooth									
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	upper jaw incisor	strong	TS23	14.5 dpc	EMAGE:6816	
<i>IRF6</i>	1	<i>Irf6</i>	MGI:1859211	upper jaw molar	strong	TS23	14.5 dpc	EMAGE:6816	
<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	upper jaw incisor	weak	TS23	14.5 dpc	EMAGE:16248	
<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	lower jaw incisor	weak	TS23	14.5 dpc	EMAGE:16248	
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	upper jaw incisor	moderate	TS23	14.5 dpc	EMAGE:11923	
<i>KRT18</i>	12	<i>Krt18</i>	MGI:96692	upper jaw molar	moderate	TS23	14.5 dpc	EMAGE:11923	
embryo									
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	surface ectoderm	strong	TS15	9.5 dpc	EMAGE:548	
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	surface ectoderm	detected	TS15	9.5 dpc	EMAGE:647	
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	embryo	detected	TS21	12.5 dpc	EMAGE:3844	
<i>MSX1</i>	4	<i>Msx1</i>	MGI:97168	extraembryonic component	strong	TS14	17 Somite no.	EMAGE:628	
<i>SPRY1</i>	4	<i>Spry1</i>	MGI:1345139	embryo	-	TS15	9.5 dpc	EMAGE:4873	
<i>SPRY1</i>	4	<i>Spry1</i>	MGI:1345139	embryo	-	TS17	10.5 dpc	EMAGE:4874	
<i>SPRY1</i>	4	<i>Spry1</i>	MGI:1345139	embryo	-	TS19	11.5 dpc	EMAGE:4875	
<i>SPRY1</i>	4	<i>Spry1</i>	MGI:1345139	embryo	-	TS20	12.5 dpc	EMAGE:4876	
<i>FGF10</i>	5	<i>Fgf10</i>	MGI:1099809	embryo	detected	TS17	10.5 dpc	EMAGE:6108	
<i>FGF10</i>	5	<i>Fgf10</i>	MGI:1099809	surface ectoderm	detected	TS17	10.5 dpc	EMAGE:3769	
<i>FGF10</i>	5	<i>Fgf10</i>	MGI:1099809	embryo		TS23	14.5 dpc	EMAGE:9080	

<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	embryo	detected	TS17	9.0 dpc	EMAGE:813
<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	embryo	detected	TS17	9.0 dpc	EMAGE:3423
<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	embryo	strong	TS18	10.5 dpc	EMAGE:3696
<i>PTCHI</i>	9	<i>Ptch1</i>	MGI:105373	embryo	-	TS23	14.5 dpc	EMAGE:21444
<i>VAX1</i>	10	<i>Vax1</i>	MGI:1277163	embryo	detected	TS12	8.0 dpc	EMAGE:252
<i>VAX1</i>	10	<i>Vax1</i>	MGI:1277163	surface ectoderm	detected	TS12	8.0 dpc	EMAGE:252
<i>KRT8</i>	12	<i>Krt8</i>	MGI:1921377	embryo	weak	TS23	14.5 dpc	EMAGE:10450
<i>RPS26</i>	12	<i>Rps26</i>	MGI:1351628	embryo	strong	TS23	14.5 dpc	EMAGE:11827
<i>ERBB3</i>	12	<i>ErbB3</i>	MGI:95411	embryo	detected	TS17	10.5 dpc	EMAGE:6113
<i>ERBB3</i>	12	<i>ErbB3</i>	MGI:95411	extraembryonic component	moderate	TS23	14.5 dpc	EMAGE:16072
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	embryo	detected	TS15	9.5 dpc	EMAGE:4868
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	embryo	detected	TS17	10.5 dpc	EMAGE:4869
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	embryo	detected	TS19	10.5 dpc	EMAGE:4870
<i>SPRY2</i>	13	<i>Spry2</i>	MGI:1345138	embryo	detected	TS20	12.5 dpc	EMAGE:4872
<i>DICER1</i>	14	<i>Dicer1</i>	MGI:2177178	embryo	detected	TS16	10.5 dpc	EMAGE:4991
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	primitive endoderm	detected	TS09	6.5 dpc	EMAGE:89
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	embryo	detected	TS11	HF Downs & Davies	EMAGE:3510
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	embryo endoderm	detected	TS11	HF Downs & Davies	EMAGE:3510
<i>GSC</i>	14	<i>Gsc</i>	MGI:95841	embryo mesoderm	detected	TS11	HF Downs & Davies	EMAGE:3510
<i>CREBBP</i>	16	<i>Cerbbp</i>	MGI:1098280	embryo	detected	TS15	9.5 dpc	EMAGE:4846
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	embryo	detected	TS15	9.5 dpc	EMAGE:6158
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	embryo	detected	TS17	10.5 dpc	EMAGE:6157
<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	embryo	detected	TS19	11.5 dpc	EMAGE:3963

<i>WNT9B</i>	17	<i>Wnt9b</i>	MGI:1197020	embryo	-	TS23	14.5 dpc	EMAGE:9281
<i>NOG</i>	17	<i>Nog</i>	MGI:104327	embryo mesoderm	detected	TS11	7.75 dpc	EMAGE:747
cranium								
<i>MMP16</i>	8	<i>Mmp16</i>	MGI:1276107	cranium	strong	TS23	14.5 dpc	EMAGE:7073
<i>NOG</i>	17	<i>Nog</i>	MGI:104327	viscerocranium	weak	TS23	14.5 dpc	EMAGE:8431

Data was derived from EMAGE database (<http://www.emouseatlas.org/emage/home.php>).

Supplementary Table 12. Mutant mouse models with OFC malformations from MGI database.

Gene	Chr.	Allelic Composition (Genetic Background)	Annotated Term	Reference	Cleft rate (%)	PMID
Cleft palate:						
<i>IRF6</i>	1	<i>Irf6</i> ^{clft1} / <i>Irf6</i> ^{clft1}	cleft secondary palate	J:160190	-	20196077
<i>IRF6</i>	1	<i>Irf6</i> ^{Gt(OST398253)Lex} / <i>Irf6</i> ^{Gt(OST398253)Lex}	failure of palatal shelf elevation	J:160190	-	20196077
<i>IRF6</i>	1	<i>Irf6</i> ^{tm1Mjd} / <i>Irf6</i> ^{tm1Mjd}	failure of palatal shelf elevation	J:160190	-	20196077
<i>IRF6</i>	1	<i>Irf6</i> ^{tm1Mjd} / <i>Irf6</i> ⁺ <i>SfnEr</i> / <i>Sfn</i> ⁺ (involves: 129S1/Sv * 129X1/SvJ * C57BL/6)	cleft palate	J:116077	-	17041603
<i>IRF6</i>	1	<i>Irf6</i> ^{tm1Mjd} / <i>Irf6</i> ^{tm1Mjd}	cleft secondary palate	J:116077	-	17041603
<i>IRF6</i>	1	<i>Irf6</i> ^{Gt(OST398253)Lex} / <i>Irf6</i> ^{Gt(OST398253)Lex} (involves: 129S5/SvEvBrd * C57BL/6)	cleft secondary palate	J:115343	-	17041601
<i>MSX1</i>	4	<i>Msx1</i> ^{tm1Rilm} / <i>Msx1</i> ^{tm1Rilm}	abnormal palatal shelf fusion at midline	J:17489	100	7914451
<i>MSX1</i>	4	(either: (involves: 129S4/SvJae- <i>Msx1</i> ^{tm1Rilm}) or (involves: 129S4/SvJae * BALB/c) or (involves: 129X1/SvJae * C57BL/6J))	cleft secondary palate	J:17489	100	7914451
<i>MSX1</i>	4	<i>Dlx5</i> ^{tm1Levi} / <i>Dlx5</i> ^{tm1Levi}	cleft secondary palate	J:104286	-	16330189

<i>MSX1</i>	4	Msx1 ^{tm1Bero} /Msx1 ^{tm1Bero} Msx1 ^{tm1Bero} /Msx1 ^{tm1Bero}	cleft secondary palate	J:42035	100	9256350
				J:104286	-	16330189
		(B6.129P2-Msx1 ^{tm1Bero})	palatal shelf hypoplasia	J:104286	-	16330189
<i>MSX1</i>	4	Msx1 ^{tm1Bero} /Msx1 ^{tm1Bero} Msx2 ^{tm1Bero} /Msx2 ^{tm1Yvia}	cleft palate	J:136241	-	18442049
		(involves: 129/Sv * BALB/c * C57BL/6 * SJL)				
<i>MSX1</i>	4	Msx1 ^{tm1Rem} /Msx1 ^{tm1Rem} Tg(Msx2-cre)5Rem/0	cleft palate	J:128624	-	17654563
		(involves: 129S6/SvEvTac * C57BL/6 * SJL)				
<i>MSX1</i>	4	Msx1 ^{tm2.1(cre/ERT2)Bero} /Msx1 ^{tm2.1(cre/ERT2)Bero} Msx2 ^{tm1Bero} /Msx2 ^{tm1Bero}	cleft secondary palate	J:194129	-	23090744
		(involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C57BL/6)				
<i>FGF10</i>	5	Fgf10 ^{tm1Wss} /Fgf10 ^{tm1Wss}	cleft secondary palate	J:90909	100	15199404
<i>FGFR1</i>	8	Fgfr1 ^{tm1Jpa} /Fgfr1 ^{tm1.1Jpa} Tg(Wnt1-cre)11Rth/0	cleft palate	J:81179	80	12514106
		(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * ICR)				
<i>FGFR1</i>	8	Fgfr1 ^{tm1Jpa} /Fgfr1 ^{tm1Jpa} Tg(Wnt1-cre)11Rth/0	cleft palate	J:81179	80	12514106
		(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * ICR)				
<i>FGFR1</i>	8	Fgfr1 ^{tm2rt} /Fgfr1 ^{tm2rt}	cleft palate	J:81179	80	12514106
<i>FGFR1</i>	8	Pdgfratm9(Pdgfra/Fgfr1)Sor/Pdgfra+ (either: (involves: 129S4/SvJaeSor) or (involves: 129S4/SvJaeSor * C57BL/6))	cleft palate	J:83560	100	12748302
<i>MMP16</i>	8	Mmp16 ^{tm1Khol} /Mmp16 ^{tm1Khol}	palatal shelf hypoplasia	J:130212	80	18022611
<i>NOG</i>	17	Osr2tm2(cre)Jian/Osr2+	cleft palate	J:149232	-	19341725

		Tg(CAG-Nog)1Ych/0 (involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6)				
<i>PTCH1</i>	9	Ptch1 ^{dl} /Ptch1 ^{dl}	absent palatal shelf	J:204468	10	23897749
<i>PTCH1</i>	9	Ptch1 ^{dl} /Ptch1 ^{tm1Mps} (involves: 129S1/SvImJ * 129X1/SvJ * C57BL/6J)	palatal shelf hypoplasia	J:204468	10	23897749
<i>VAX1</i>	10	Vax1 ^{tm1Gr1} /Vax1 ^{tm1Gr1} (involves: 129S1/Sv * C57BL/6)	cleft palate	J:58996	100	10601035
<i>VAX1</i>	10	Vax1 ^{tm1Gr1} /Vax1 ^{tm1Gr1} Vax2 ^{tm1Gr1} /Vax2 ^{tm1Gr1} (involves: 129S1/Sv)	cleft palate	J:98488	-	15905411
<i>VAX1</i>	10	Vax1 ^{tm1Pgr} /Vax1 ^{tm1Pgr} (either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6) or (involves: 129S1/Sv * 129X1/SvJ * NMRI))	cleft palate	J:58997	100	10601036
<i>SPRY2</i>	13	Ednrbs-36Pub/Ednrbs+ Spry2tm1.1Mrt/Spry2+ (involves: 101/R1 * 129P2/OlaHsd * C3H/R1 * C57BL/6J)	cleft secondary palate	J:125229	-	17693063
<i>SPRY2</i>	13	Ednrbs ^{s-36Pub} /Ednrbs ^{s-36Pub} Tg(Spry2)2Tpo/0 (B6.Cg-Ednrbs ^{s-36Pub} Tg(Spry2)2Tpo)	cleft secondary palate	J:125229	-	17693063
<i>SPRY2</i>	13	Ednrbs ^{s-36Pub} /Ednrbs ^{s-36Pub} Tg(Spry2)69Tpo/0 (B6.Cg-Ednrbs ^{s-36Pub} Tg(Spry2)69Tpo)	cleft secondary palate	J:125229	-	17693063
<i>GSC</i> ; <i>MSX1</i>	14; 4	Gsc ^{tm1Pgr} /Gsc ^{tm1Pgr} Msx1 ^{tm1Rilm} /Msx1 ^{tm1Rilm} (involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)	cleft palate	J:59750	-	10512191
<i>CREBBP</i>	16	Crebbp ^{tm2Pkb} /Crebbp ^{tm2Pkb} (involves: 129P2/OlaHsd * C57BL/6)	cleft secondary palate	J:103607	50	16237459

<i>WNT9B</i>	17	Pbx1 ^{tm1Mlc} /Pbx1 ⁺ Wnt9b ^{tm1Amc} /Wnt9b ^{tm1Amc} Foxg1 ^{tm1} (cre)Skm/Foxg1 ⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * 129X1/SvJ)	cleft palate	J:178316	100	21982646
<i>WNT9B</i>	17	Wnt9b ^{tm1Amc} /Wnt9b ^{tm1Amc} Foxg1 ^{tm1} (cre)Skm/Foxg1 ⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	cleft palate	J:178316	100	21982646
<i>WNT9B</i>	17	Wnt9b ^{tm1.1Amc} /Wnt9b ^{tm1.1Amc} (involves: 129X1/SvJ * C57BL/6 * CBA)	cleft palate	J:100575	-	16054034

Cleft lip:

<i>WNT9B</i>	17	Pbx1 ^{tm1Mlc} /Pbx1 ⁺ Wnt9b ^{tm1Amc} /Wnt9b ^{tm1Amc} Foxg1 ^{tm1} (cre)Skm/Foxg1 ⁺ (involves: 129P2/OlaHsd * 129S6/SvEvTac * 129X1/SvJ)	cleft upper lip	J:178316	100	21982646
<i>WNT9B</i>	17	Wnt9b ^{tm1Amc} /Wnt9b ^{tm1Amc} Foxg1 ^{tm1} (cre)Skm/Foxg1 ⁺ (involves: 129P2/OlaHsd * 129X1/SvJ)	cleft upper lip	J:178316	-	21982646
<i>WNT9B</i>	17	Wnt9b ^{clfl} /Wnt9b ^{clfl} (AEJ.A/Jur)	cleft upper lip	J:22596	-	3491125
				J:92341	24	15329828
				J:69826	24	11353389
<i>WNT9B</i>	17	Wnt9b ^{clfl} /Wnt9b ^{clfl} clf2/clf2 (AEJ.A/Jur)	cleft upper lip	J:25484	20	7601909
				J:92341	24	15329828
				J:69826	24	11353389
<i>WNT9B</i>	17	Wnt9b ^{clfl} /Wnt9b ^{clfl}	cleft upper lip	J:92341	24	15329828

<i>WNT9B</i>	17	clf2/clf2+(AEJ.A/Jur) Wnt9b ^{tm1.1Amc} /Wnt9b ^{tm1.1Amc} (involves: 129X1/SvJ * C57BL/6 * CBA)	cleft upper lip	J:69826 J:100575	24 -	11353389 16054034
--------------	----	--	-----------------	---	---------	----------------------

Data was derived from the database of MGI (<http://www.informatics.jax.org/>).

Supplementary Table 13. Syndromic OFC from OMIM database.

Gene	Chr.	CL/P Syndrome	Phenotype OMIM number	Main phenotypes	PMID	Cleft type
<i>IRF6</i>	1	Van der Woude syndrome	<u>119300</u>	CL/P, lip pit	12219090	CL/P
		Popliteal pterygium syndrome	<u>119500</u>	popliteal/intercrural pterygium, syndactyly fingers and toes, congenital ankyloblepharon filiforme, cryptorchidism, bifid scrotum, hypoplastic vagina/uterus, lip cyst, CL/P, lip pit	12219090	CL/P
<i>MSX1</i>	4	Tooth agenesis, selective, 1, with or without orofacial cleft	<u>106600</u>	tooth agenesis, CL/P	10742093	CL/P
<i>TFAP2A</i>	6	Branchio-oculo-facial syndrome	<u>113620</u>	branchial cleft sinus defects, ocular anomalies, CL/P	24783654	CL/P
<i>FGFR1</i>	8	Hartsfield syndrome	<u>615465</u>	holoprosencephaly, ectrodactyly, mental retardation, CL/P	19504604	CL/P
		Kallmann syndrome	<u>147950</u>	idiopathic hypogonadotropic hypogonadism, anosmia, sensorineural hearing loss, CL/P	12627230 15001591	CL/P CPO
<i>PTCH1</i>	9	Gorlin syndrome	<u>109400</u>	basal cell carcinomas, jaw cysts, ovarian calcification or fibroma, ophthalmic abnormalities, CL/P	8681379	CL/P
<i>VAX1</i>	10	Microphthalmia, syndromic 11	<u>614402</u>	microphthalmia, small optic nerve, CLP, agenesis of corpus callosum, height in third centile, weight in third centile, head circumference in third centile	22095910	CLP
<i>RPS26</i>	12	Diamond-Blackfan anemia 10	<u>613309</u>	macrocytic anemia, increased fetal hemoglobin, increased erythrocyte adenosine deaminase activity, reticulocytopenia, bone marrow shows decreased erythroid progenitors, short stature, CPO	24942156	CPO

Data was derived from Online Mendelian Inheritance In Man database (OMIM, <http://omim.org/>).

Supplementary Table 14. Biological categories by literature review.

Category	Chr.	Description	PMID
<u>morphogenesis and development</u>			
bone morphogenesis			
<i>IRF6</i>	1	mutations associated with impaired morphogenesis of the lip and palate; mutations may lead to abolish the DNA binding activity in the developing craniofacial region.	12964020; 12219090
<i>MSX1</i>	4	encodes a transcription factor that is highly expressed during embryogenesis and postnatal development in bone.	24929242
<i>MSX1</i>	4	Mutations of the <i>MSX1</i> gene in humans are associated with cleft palate and (or) tooth agenesis.	24929242; 7914451
<i>MMP16</i>	8	Combined loss of MT1-MMP and MT3-MMP leads to severe craniofacial developmental defects.	18022611
<i>VAX1</i>	10	associated with non-syndromic orofacial clefts.	25171615; 25081408; 22095910
<i>SUOX</i>	12	The findings suggest an important role for sulfite oxidase (<i>SUOX</i>) in bone development.	20865119
<i>DICER1</i>	14	Loss of <i>Dicer1</i> activity in <i>Col2a1</i> chondrocytes causes lethal tracheomalacia.	21945074
<i>WNT9B</i>	17	a role for WNT genes in the pathogenesis of cleft lip/palate.	20890934; 18413325; 18181213; 16998816
<i>WNT9B</i>	17	regulatory link between <i>WNT9B</i> and FGF signaling during lip and upper jaw development; regulate midfacial development and lip fusion.	22461561; 16496313
<i>NOG</i>	17	too little expression of <i>NOG</i> , a growth antagonist, or overexpression of <i>GDF5</i> , a growth agonist, results in cartilage overgrowth and bony fusion.	17994231
<u>Signaling</u>			
MAPK signaling			
<i>FGF2</i>	4	<i>FGF2</i> differentiates into tenocytes and the MAPK pathway is key in differentiation.	24008926

<i>SPRY1</i>	4	augmenting ERK-MAP kinase activity through inhibition of SPRY1; downstream of the GRB2-SOS complex to selectively uncouple growth factor signals from Ras activation and the MAPK pathway.	19043405; 11585837
<i>FGF10</i>	5	stimulatespreadipocyte proliferation through the Ras/MAPK pathway;also stimulates adipogenesis by inducing the expression of pRb through the Ras/MAPK pathway.	21696361
<i>FGFR1</i>	8	FGFR1-induced epithelial to mesenchymal transition through MAPK/PLC γ /COX-2-mediated mechanisms.	22701738
<i>GADD45G</i>	9	Gadd45 proteins are associated with signaling mediated by p38 mitogen-activated protein kinases (MAPK). Gadd45 proteins can contribute to p38 activation either by activation of upstream kinase(s) or by direct interaction.	24104470
<i>SPRY2</i>	13	ERK-MAPK signaling pathway was regulated by Sprouty2 ; Inactivation of Spry2 accelerates AKT-induced hepatocarcinogenesis via activation of MAPK and PKM2 pathways.	23239100; 22617155
BMP signaling			
<i>MSX1</i>	4	MSX1 expression was regulated by BMP signaling, and in particular that its expression was upregulated by SMAD8 activity.	16101586
<i>NOG</i>	17	noggin inhibits BMP signaling by blocking the molecular interfaces of the binding epitopes for both type I and type II receptors.	12478285
WNT signaling			
<i>GSC</i>	14	Higher gsc doses resulted in complete secondary axes and long-range signaling, correlating with repression of BMP and Wnt signals.	19369398
<i>WNT9B</i>	17	Wnt9b signal through the canonical Wnt signaling pathway to regulate midfacial development and lip fusion.	16496313
epidermal growth factor receptor signaling pathway			
<i>IRF6</i>	1	a transcription factor required for the differentiation of skin	22931925; 17041601
<i>SPRY1</i>	4	modulators and feedback inhibitors of signalling by epidermal growth factor (EGF) and fibroblast growth factor (FGF).	16954433
<i>ERBB3</i>	12	a member of the epidermal growth factor receptor family.	25000258
<i>SPRY2</i>	13	feedback regulator of EGFR trafficking and signaling; EGFR degradation through downregulation of the	23868981; 19364817

EGFR-stabilizing protein Sprouty2 (Spry2).

ERK1/2 cascade

<i>SPRY1</i>	4	deficiency led to heightened EPO/EPOR activation of Erk1/2.	22508938
<i>FGF10</i>	5	FGF10 mediated RAS-regulated ERK1/2 signaling.	21764747
<i>SPRY2</i>	13	function to modulate signaling via the RAS/ERK1/2.	23150596

fibroblast growth factor receptor signaling pathway

<i>SPRY1</i>	4	modulators and feedback inhibitors of signalling by epidermal growth factor (EGF) and fibroblast growth factor (FGF).	16954433
<i>FGF10</i>	5	FGF10 is an FGFR ligand; Shh is a downstream target of Fgf10/Fgfr2b signaling.	15199404; 16501574
<i>FGFR1</i>	8	FGF signaling mediates cilia length through an Fgf8/Fgf24-Fgfr1-intraflagellar transport pathway.	OMIM; 19242413
<i>ERBB3</i>	12	ErbB3 is a functional component of FGFR2-amplified cell growth.	18381441
<i>SPRY2</i>	13	antagonism of FGF signaling.	15809037
<i>NOG</i>	17	noggin expression is suppressed by FGF2 and syndromic FGFR signaling.	12687003

Notch signaling pathway

<i>CREBBP</i>	16	Altered CREBBP structure resulted in changes in expression of basal levels of components of Notch.	20207472
---------------	----	--	----------

Rab protein signal transduction

<i>RAB5B</i>	12	presumably involved in vesicular trafficking at the plasma membrane.	1541686
--------------	----	--	---------

Ras protein signal transduction

<i>FGF2</i>	4	the FGF2-Ras-MAPK-dependent mechanism that maintains and modulates the LEC trait.	24357720
<i>SPRY1</i>	4	inhibited the Ras/Raf (164760)/Mapk pathway by preventing Ras activation.	11585837; 12402043
<i>CDK2</i>	12	ras-induced tumors are more susceptible to CDK2 ablation than myc-induced tumors; Ras, along with the activation of additional pathways, is required for the generation of G1 CDK activity.	17942901; 9163430
<i>SPRY2</i>	13	inhibited the Ras/Raf (164760)/Mapk pathway by preventing Ras activation.	11585837; 12402043

cell-related

apoptosis process

<i>MSX1</i>	4	msx1 promotes cell death.	15501222; 15705871
-------------	---	---------------------------	--------------------

<i>CCDC26</i>	8	prominent expression in embryo; Knockdown of RAM promoted 9-cis RA-induced differentiation and TRAIL-triggered apoptosis.	16449964
<i>GADD45G</i>	9	encodes a ubiquitously expressed protein that is often induced by DNA damage and other stress signals associated with growth arrest and apoptosis.	24104470
<i>PTCH1</i>	9	Ptch1 promotes cell and tissue-specific apoptosis via its regulation of Caspase9 (Casp9) activity and mitochondrial function.	25292199
<i>KRT18</i>	12	Keratins 8 and 18 (K8/K18) provide anti-apoptotic functions upon liver injury.	20538000
<i>KRT8</i>	12	Keratin-deficient mice displayed significantly lower numbers of apoptotic hepatocytes than wt animals; Keratins 8 and 18 (K8/K18) provide anti-apoptotic functions upon liver injury.	22449798; 20538000
<i>NTN1</i>	17	functioned in cell survival by inhibiting the proapoptotic activity of Dcc.	18796601
cell cycle			
<i>IRF6</i>	1	promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner.	18212048
<i>GADD45G</i>	9	cooperate in activation of S and G2/M checkpoints following exposure of cells to UV irradiation.	12124778
<i>CDK2</i>	12	cyclin E binds to CDK2 to promote the transition of cells from G1 to S phase ; cyclin A binds to CDK2 to progress the cell cycle through the S phase and G2/M transition.	21319273 ; 18372919; 18372919; 20195506
cell differentiation			
<i>FGF2</i>	4	FGF2 was found to up-regulate to FGFR3 until the peak level of FGFR3 mRNA expression, while in hypertrophic chondrocytes, FGFR3 appeared to cause the differentiation of chondrocytes.	15878293
<i>FGFR1</i>	8	FGFR signaling promotes chondrocyte differentiation from condensed mesenchyme.	11585811
<i>GADD45G</i>	9	GADD45G as an instructor of LT-HSC differentiation under the control of differentiation-promoting cytokine receptor signaling.	25068120
<i>MAFB</i>	20	down regulation of Mafb are crucial for osteoclastogenesis.	23132958
cell division			
<i>CDK2</i>	12	regulating various events of eukaryotic cell division cycle.	25386824
cell migration			
<i>FGF2</i>	4	up-regulatedcten modulates cell migration induced by FGF2.	23625726

<i>FGF10</i>	5	stromal FGF10 induces migration and invasion in pancreatic cancer cells through interaction with FGFR2.	18594526
<i>FGFR1</i>	8	Fgfr1 patterns the pharyngeal region to create a permissive environment for neural crest cell migration.	12514106
<i>NTN1</i>	17	stimulates proliferation, induces migration, and promotes adhesion of endothelial cells and vascular smooth muscle cells with a specific activity comparable to PEGF and PDGF.	15520390
cell proliferation			
<i>IRF6</i>	1	a key determinant of the keratinocyte proliferation-differentiation switch ; a developmental feedback regulatory loop between p63 and IRF6 for the control of proliferation of epithelial cells; a primary Notch target in keratinocytes, which contributes to the role of this pathway in differentiation and tumour suppression.	17041603; 20424325; 21909072
<i>MSX1</i>	4	Msx1/Msx2 double-null mutation prevented full activation of Stra8, a gene required for meiosis.	22071108
<i>SPRY1</i>	4	inhibit cell proliferation.	15342396
<i>MMP16</i>	8	distinct and specific functions for MT1-MMP and MT3-MMP in skeletal development.	18470538
<i>ERBB3</i>	12	NRG1-driven/activated-ErbB3 autocrine loop in promoting cell proliferation in human ovarian cancer cells; Proliferation of Colorectal Cancer Cells is Mediated by Either ErbB3/ErbB2 or ErbB3/C-MET Signaling Pathways.	20227043; 24205104
<i>SPRY2</i>	13	inhibiting Spry2 expression in renal cell carcinoma promotes proliferation ; loss of Spry2 was associated with an increase in palate mesenchymal cell proliferation.	21195053; 23688375
<i>NTN1</i>	17	stimulates proliferation, induces migration, and promotes adhesion of endothelial cells and vascular smooth muscle cells with a specific activity comparable to PEGF and PDGF.	15520390
cellular response to stimulus			
<i>CREBBP</i>	16	CBP/catenin signaling in enhancing and maintaining the leukemia stem/initiating-like cell population under hypoxic conditions; induce MMP1 expression during prolonged hypoxia and regulates cell migration and invasion in cancer cells.	24720539 ; 23775082
<i>CREBBP</i>	16	induction of Egr1 by UV-C irradiation leads to repression of p300/CBP transcription; p300 and CBP act redundantly in UV lesions.	15225550; 23275565
<u>metabolic process</u>			
<i>ABCA4</i>	1	clearance of all-trans-retinal produced by the visual (retinoid) cycle required for vision.	18658157; 19304658

<i>MMP16</i>	8	zinc-binding endopeptidases that degrade various components of the extracellular matrix.	OMIM
<u>histone-related</u>			
<i>CREBBP</i>	16	CBP and its close paralog p300 are transcriptional co-activators with intrinsic histone acetyltransferase activity.	22387215
<u>phospholipid-related process</u>			
<i>ABCA4</i>	1	an N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine importer.	24097981; 22735453; 15471866
<i>FGF2</i>	4	FGF2 binding phosphorylates both extracellular signal-related kinase (ERK) and focal adhesion kinase.	10959077; 15174091
<i>PPAPDC1B</i>	8	a novel type of mammalian phosphatidate phosphatase.	17590538
<i>DDHD2</i>	8	a phospholipase that hydrolyzes sn-1 ester bonds of phospholipids, producing 2-acyl-lysophospholipids and fatty acids.	20932832
<u>others</u>			
eye morphogenesis			
<i>VAX1</i>	10	critical for the development of the mammalian binocular visual system; Vax1 expressed restricted to the optic stalk.	25201875; 10421837
<i>WNT9B</i>	17	in the ocular surface ectoderm.	16258938
brain morphogenesis			
<i>MSX1</i>	4	Driving dopaminergic neuronal differentiation of ventral mesencephalic progenitors.	18385323
<i>PTCH1</i>	9	co-ordinated development of the brain and face is dependent in part upon XIAP mediation of Hh/Ptch1-regulated cell survival and apoptosis during embryogenesis.	25292199
<i>VAX1</i>	10	regulates the guidance properties of a set of anterior midline cells that orchestrate axon trajectories in the developing mammalian forebrain.	10601035
<i>GSC</i>	14	the morphogenetic function of the rostral AML requires Gsc activity.	10751169
<i>MAFB</i>	20	the dual function of Mafb in both segmentation and specification of anteroposterior identity in the hindbrain.	12490204
lung development			
<i>FGF10</i>	5	serves as an essential regulator of lung and limb formation.	9988217; 9916808
<i>SPRY2</i>	13	encode negative regulators of FGF10 mediated RAS-regulated ERK1/2 signaling, as essential for controlling airway shape change during development through an effect on mitotic spindle orientation.	21764747

limb morphogenesis

<i>MSX1</i>	4	Msx1 antagonizes the myogenic activity of Pax3 in migrating limb muscle precursors via direct protein-protein interaction.	10529415
<i>FGF10</i>	5	induces formation of the apical ectodermal ridge and is necessary for limb development.	22965740
<i>FGFR1</i>	8	mutations in FGFR1 and FGFR2 with disorders of limb patterning.	11389462
<i>PTCH1</i>	9	Ptch1 and Ptch2 are co-expressed in the developing mouse limb bud; modifications affecting the Ptch1 cis-regulatory landscape have contributed to evolutionary diversification of artiodactyl limbs.	25448692; 24990743
<i>DICER1</i>	14	essential for proper limb bud positioning.	21256124
<i>NOG</i>	17	BMP binding affinity of site-specific variants of noggin was correlated with alterations in bone formation and apoptosis in chick limb development.	12478285

ear morphogenesis

<i>MSX1</i>	4	each mutant mouse displays intriguing facial abnormalities including those of middle ear ossicles.	10512191
<i>FGFR1</i>	8	essential for the normal formation of the organ of Corti and that phenotype severity observed in Fgfr1 mutants is dependent on the dose of FGFR1.	19820032
<i>SPRY2</i>	13	negatively regulates FGF8 signaling during pillar cell formation and for hearing function.	15809037
<i>DICER1</i>	14	Removal of Dicer from sensory epithelium caused abnormal growth and subsequent degeneration of mechanosensory hair cells.	19416898
<i>GSC</i>	14	displays intriguing facial abnormalities including those of middle ear ossicles.	10512191
<i>MAFB</i>	20	loss of hindbrain kr/mafB expression in mutant mice results in an altered inductive signal from the hindbrain to the developing ear that ultimately leads to the inner ear malformations.	16325169

other organs morphogenesis

<i>IRF6</i>	1	plays important cell-autonomous and non-cell-autonomous roles in muscular differentiation and cytoskeletal formation in the tongue; mice deficient for Irf6 have abnormal skin, limb and craniofacial development; TGF β /SMAD4/IRF6 signaling cascade might be a well-conserved mechanism in regulating multiple organogenesis.	15472655 ; 23451037; 17041601; 23406900
<i>FGF2</i>	4	FGF2 delays tectal neurogenesis and, thereby, triggers a cascade of changes in tectum size and morphology.	24265789

<i>SPRY1</i>	4	positive (GDNF) and inhibitory (Sprouty1) signals have to be finely balanced throughout renal development to prevent hypoplasia or cystic hyperplasia.	17022962
<i>FGF10</i>	5	Fgf10 +/- mice were found to have aplasia of lacrimal glands and hypoplasia of salivary glands.	15654336
<i>GADD45G</i>	9	essential for primary sex determination, male fertility and testis development.	23516551
<i>RAB5B</i>	12	a small GTPase protein that regulates the motility and fusion of early endosomes.	25605758
<i>ERBB3</i>	12	Myocilin mediates myelination in the peripheral nervous system through ErbB2/3 signaling.	23897819 ;
<i>ERBB3</i>	12	NRG-1 β /ErbB3/CREB signalling at the pre-mesoderm stage for stem cell cardiac differentiation.	24364879; 12134143
<i>GSC</i>	14	the expression of Gsc in the appendicular skeleton during mid- to late organogenesis, including in the shoulder and hip joint region, and in several ligaments and adductor muscles.	9566956
<i>DICER1</i>	14	Dicer-dependent processes in limiting the timespan of cortical neurogenesis.	24012747
<i>CREBBP</i>	16	CBP/p300 and associated transcriptional co-activators exhibit distinct expression patterns during murine craniofacial and neural tube development.	19598128
<i>WNT9B</i>	17	function during the early phase when the cap mesenchyme is induced to undergo morphogenesis into a nephron; convergent extension of the tubular epithelial cells; balances progenitor cell expansion and differentiation during kidney development.	24445433; 21852398; 21350016
<i>WNT9B</i>	17	a common organizing signal regulating diverse components of the mammalian urogenital system.	16054034
<i>NOG</i>	17	In the developing frog, the noggin protein also mimics the activity of the Spemann organizer, which can make dorsal tissue out of ventral tissue.	OMIM
<i>NOG</i>	17	Nog(-/-) embryos displayed reduction in the dorsal foregut endoderm.	GENE
<i>NOG</i>	17	BMP antagonism is required in both the node and LPM to facilitate L-R axis establishment in the mammalian embryo.	18550712

axon guidance

<i>FGFR1</i>	8	FGFR1 is prominent in the cytoplasm of photoreceptors, and in their axon terminals.	12708794
<i>NTN1</i>	17	attract spinal commissural axons and repel trochlear axons in vitro.	8978605

angiogenesis

<i>FGF10</i>	5	FGFs interact with FGF receptors, which are a family of tyrosine kinase membrane bound receptors with extracellular ligands, and trigger transducing extracellular cues to elicit diverse biological responses such as mitogenesis, angiogenesis, cell proliferation, development, differentiation and cell migration.	25446127
<i>FGFR1</i>	8	angiopoietins as downstream effectors of FGFR1 activation in vivo; FGF2 induces endothelial cell migration and angiogenesis through two classes of receptors: receptor tyrosine kinases, such as FGFR1, and heparan sulfate proteoglycans, such as syndecan 4.	17297442; 22569333
<i>DICER1</i>	14	Dicer1 is essential for normal endothelial angiogenic processes; Dicer1-dependent miRNA expression may be a potential mechanism underlying impaired angiogenesis and cerebromicrovascular rarefaction in aging.	23239824

Data was derived from the database of Pubmed (<http://www.ncbi.nlm.nih.gov/pubmed>) and summarized from the related literature.

Supplementary Table 15. Primer sequences.

SNP_ID	2nd-PCR	1st-PCR	UEP_SEQ
rs7554547	ACGTTGGATGTGAGGGCGAATAGATGTTGG	ACGTTGGATGCCTCATCTGTAAAACAGGAC	gagGACCTCCAGTATTCCTGCAAGG
rs9439713	ACGTTGGATGCCCTCTCTCTCAAATTAGG	ACGTTGGATGTCTGTGTCCCCTGTATGG	TCAAATTAGGTTCTGGTTGG
rs742071	ACGTTGGATGTTGCAATCCTGGTTAAGGAC	ACGTTGGATGTTGATCCACTGTAACCGTGC	gggTGTTGTTGCAACGGT
rs11582254	ACGTTGGATGAGTGTGAGCCACACTGTGGT	ACGTTGGATGAGCTGCCTGTTCTGATCACT	ggfTGAGGCCTAGCTTCAT
rs1883567	ACGTTGGATGGGGCTCTGGAGGTTCAAATC	ACGTTGGATGCAACCCTGTCTCTAAAAAGC	tcGGTTCAAATCCAATCCTG
rs6588607	ACGTTGGATGCTGAGTCTTCCCAATAAGC	ACGTTGGATGGACTCATGCCTGTGATGTAG	CCAATAAGCTACATTGAATTTTTT
rs1331862	ACGTTGGATGCCATTCATTAACCTGTTCTC	ACGTTGGATGTAGGAGATCAGGTGCCATAC	gtcACCTGTTCTCAGGTTAGTAAGT
rs277354	ACGTTGGATGGCTGTTAATAATTCCCAGAG	ACGTTGGATGTAGACCACCAAAACTTGCTG	gCCCAGAGAGAATAATCTGC
rs7367789	ACGTTGGATGTTACTCAAGGCCATATCCCC	ACGTTGGATGGTTGTGTAAGTGTGATTGGC	CCTGAAATACTACAGCCA
rs4147827	ACGTTGGATGCTGTAGCAGGTGAGCATTAG	ACGTTGGATGTCTCAACCTGGGCCGAGTAT	ggGAGCATTAGTACAATGGGCT
rs17461953	ACGTTGGATGAATCTACTTGGGAGGAAGC	ACGTTGGATGGGCAAACCTTCTACTCATCCC	GGAAGCTGTTTCTCACA
rs481931	ACGTTGGATGTGCTGTTTCAGGGAAAGGCAC	ACGTTGGATGTCTCCAAATTCTCCCCTCCC	tTCCAGCACACAGGGG
rs4147803	ACGTTGGATGCATCCCTGTCCTTGACGCTT	ACGTTGGATGGTCTGAGCTGCTGAGAAAAC	TCCTTGACGCTTAACTGC
rs12047887	ACGTTGGATGCCCTTGCCACTTGGATCTTA	ACGTTGGATGTCAAAGCAGGGGATCCATTC	cGTCACCTTCACAAACCTTT
rs4839542	ACGTTGGATGCTGCTTGCCATTACATGAC	ACGTTGGATGAGAGCAAGCATTGGGCATTA	TGTTTTTCCTCTCTGAGT
rs10918593	ACGTTGGATGATGTTGGAGATGGATGTTAC	ACGTTGGATGCACACAACCATGGCACATAG	cGATGGATGTTACTTCGTTT
rs861020	ACGTTGGATGTGAAAACCCAAATGGCCAAG	ACGTTGGATGCACCTGTTGTTAATGGCTAC	aaacTGGCCAAGACAGAAAC
rs642961	ACGTTGGATGTCTTACCCAAAGGCCTGAAG	ACGTTGGATGGTCAAGGATAGAGCATGCTG	tgatGCCTGAAGTAATACCCCAG
rs2064163	ACGTTGGATGGGCCTGGTGGTTAAGAAAAC	ACGTTGGATGCAACCATGCATTAGTCCTCC	atgtTGGTTAAGAAAACAAAATGAATTT
rs9430019	ACGTTGGATGCTCTGAAACAGCAGCAGTTA	ACGTTGGATGTTTCTTTTGACAGTACAGCC	cATAAATTCCTTTTTTGCTACAGTTT
rs11583395	ACGTTGGATGGGGATTAAAATGGCTGAGGG	ACGTTGGATGCGTCTTTTACAAATAACCTC	ccgcGGGCATTTAAAAAAATTTATGCT
rs201830371	ACGTTGGATGGTTCTTAAAGCTTTGACACTC	ACGTTGGATGACTAGGAATCCCTAACCGTG	ctcgTGAATTCATCTGCACA
rs287980	ACGTTGGATGTGACTGATGATCTTGACGTG	ACGTTGGATGGAGCAACTCTTGCTCATTG	aTGATGATCTTGACGTGATATAC

rs287982	ACGTTGGATGACTTGCTTCATGTGGCTTCC	ACGTTGGATGGCATTAGATGTCAGGGACAG	ccCTCCTCTGGTTCTCTTC
rs10172734	ACGTTGGATGGTGTTTAAGCTTTCTGAGTC	ACGTTGGATGTCGGCATTAAACCTTACAGGG	GCTTTCTGAGTCTTAACCTC
rs7552	ACGTTGGATGCTTTGCTACTGGAGTCCTTT	ACGTTGGATGTCCCAGAGAGATAACACATC	aTACTGGAGTCCTTTAACAACA
rs7590255	ACGTTGGATGGTTCTTTATCTTTGTCCTAC	ACGTTGGATGCAATCTGAAAGAACCATCCC	gtagTTTCTCTCTCATTTCAAAGCA
rs17491637	ACGTTGGATGTTAATACAGTTTTAGATCAG	ACGTTGGATGGTGGGTCCATCAACAGAAAC	aagACAGTTTTAGATCAGATGATT
rs11677862	ACGTTGGATGAAAGATGTTTTATGATGCC	ACGTTGGATGGCAACTGTTTTTCCTAACTC	ATGTTTTATGATGCCTGTATG
rs12623132	ACGTTGGATGCAAAACATGCTGCTTTAGAG	ACGTTGGATGATTCTAAAATCAACCTACC	agTGAATACTTGGTTAGAGATGA
rs6734545	ACGTTGGATGAGAAGACTGGCTGGGAAAAG	ACGTTGGATGGGAGACATGAGGAGGAAATC	GGCTGGGAAAAGTTGATGAG
rs77866552	ACGTTGGATGGCCAGTTACTGAATGTGGTC	ACGTTGGATGAGAGTCAGCAAGGAGAAATC	CAGCTGTGGTTTTGTCT
rs78991648	ACGTTGGATGGCTGGCTTTAATATTTCTG	ACGTTGGATGTGGGTCTAATTACAGTCAC	ctaCTGTTTTTAAGACCTTTTTTCT
rs1395165	ACGTTGGATGGGTTTTGTTCTTTAACCGCC	ACGTTGGATGACAGGCAGTCTCTAGACCTC	tcACCGCCTTCCAGCAT
rs12485312	ACGTTGGATGCTCACACTATGGGAGTAGAC	ACGTTGGATGCAACCATGCTCATCTGATAG	ATGGGAGTAGACAGATAAGTGA
rs1038294	ACGTTGGATGGAGTTACTTACCTGAGGGTC	ACGTTGGATGAGGATATGTACCTTTGTTGC	GTCATAGATCAATATAGTTAGAGTC
rs1688766	ACGTTGGATGATAAACTCTGGCAACCTACC	ACGTTGGATGGGCAAGACAGTAGTCTCTTC	aacgCTGGCAACCTACCTCAGGA
rs9847858	ACGTTGGATGGAAGGTTGGCAAGTTGCATC	ACGTTGGATGCTGCCAAAGAGGAAATCGAC	AACAGCTGCTCTTGT
rs10936656	ACGTTGGATGAGCAGAAAGGTATGAGCAGG	ACGTTGGATGCTTTTCCTCCAATGTTCCCC	acgATAGTACATGGCATGAGTG
rs17597256	ACGTTGGATGACCAGGGAAAACATGGGTG	ACGTTGGATGGGAGGGAGATAAATGGAATC	ccccTGTCACCTTTCCCGACC
rs7649443	ACGTTGGATGGGTATATGACATTTCTTCC	ACGTTGGATGAAACCACTGACAGCAATCGC	GTTCTTCTTGGCCCTTA
rs34246903	ACGTTGGATGTTCCCACTGTTTCTGTGAG	ACGTTGGATGGACCTATGGAGTTCTCAATG	ggggtTGAGAATTCATTAAGGATCAC
rs1907989	ACGTTGGATGTTTGAGGCTTCTCTGATCC	ACGTTGGATGCAGTAGAAAGGGTTCCCTTG	TTCTCAAAGAAACATCACTG
rs7692299	ACGTTGGATGAAAGGTGCTCAATACATGGG	ACGTTGGATGCAAAACACATTCTAGTCCAGC	GGATGATGGAAAAATATTTTATTATGA
rs908822	ACGTTGGATGCAGAAATGCTCCAACAGCAG	ACGTTGGATGCTGCTGCAGGGAAGCAGGG	GGCTATCAAAGCCCC
rs7686589	ACGTTGGATGCTTCTATCAGAGTTGGTATC	ACGTTGGATGCAGTTTAGCCATGGTTTCTC	aagcGTTGGTATCTTTAACTTGACC
rs66509882	ACGTTGGATGGTAGACCATCAAAGAGCAG	ACGTTGGATGCCTCCCAAAGTCTGGAGT	tgATGAGGAATTTCTAAAAGACAGATC
rs4417922	ACGTTGGATGAGGTTATGGTCCACAGACAG	ACGTTGGATGTCACAGCTTCTAGTCAGCAG	ccggCCACAGACAGTCATTTATG
rs2333571	ACGTTGGATGCATGGGTACTCTGGACAAAG	ACGTTGGATGGGACATCTTTGAATAGTGTG	TGGAGAGGGACAGTG

rs13124707	ACGTTGGATGCTGGCTGTCAATCTTGCAAT	ACGTTGGATGGAGTATAGTATGATCTATG	aaTATCTCCCTCTCTCTCTTC
rs10462065	ACGTTGGATGGTGTGGTTCTAAAGCTGCTG	ACGTTGGATGGGTCTATAGGAGTGTGTAG	GCTGGCAATTTAGGTG
rs4242107	ACGTTGGATGTTGGGTCTTACAGTCTAGAG	ACGTTGGATGTCTTACTACTCCCTGTCTTC	gTTACAGTCTAGAGAGAATAGAG
rs10462084	ACGTTGGATGTCTGCTGCCTTATTCAAGCC	ACGTTGGATGAAAGGTAGAAGCAGACAGCC	cttagTCAAGCCAGTACACTC
rs7771515	ACGTTGGATGAAAGGCACTGGGCTCTGAAG	ACGTTGGATGTTCCCTTCACTACTCATTC	tcctTGGGCTCTGAAGAAAAGAGG
rs9381107	ACGTTGGATGACTTACTACCTGCCCTGTTG	ACGTTGGATGCATCCACTGGGATCTTTAAG	gaggaCCTGTTGCTCAAAAAAGAG
rs11965246	ACGTTGGATGGGTTGACTCATAAGTGATGG	ACGTTGGATGTTTCAGGTAGTGGGCACAATG	aataACACTTTTGCTACCAAAAGAAA
rs12203226	ACGTTGGATGCTCCCTACTCCCAAAATTC	ACGTTGGATGCTTCTTAAAGACCCTAGCTC	agcaCTAACTCCCAGTATCTCC
rs10260512	ACGTTGGATGCCCTTCTAAAGCTCAGATCC	ACGTTGGATGGGAGATGGACTTCAGGAAAC	tcTTTGAGATTTTCAGGAAATAGT
rs76523544	ACGTTGGATGGGAAGAAAATGTTTGTGCC	ACGTTGGATGGAAAGTGGTCAGAGTGTGTC	TGCCCTCTAATTTAATTCAA
rs10256809	ACGTTGGATGCTGAAGAGCTATGCAGTGGG	ACGTTGGATGGCTATGACCATTGTGCTGAG	CTCAGAGATGCTCCAG
rs17227506	ACGTTGGATGTCAGACAGGGCCCTATACAC	ACGTTGGATGATCAGATTTCTGACTAGCTC	gatagGTTTACTGGAAGACTGGAATTT
rs13317	ACGTTGGATGCAAACTAGCCTCAGGTGAC	ACGTTGGATGAAACCCAGACATGTGTCTGC	CCTGCACTTAGAAGCAC
rs3925	ACGTTGGATGCAAGCGTTTCCAGTCTTAG	ACGTTGGATGGATGCTCTTATCATGCACCC	ccgtgTCCCAGTCTTAGCCCTGTGT
rs12543318	ACGTTGGATGGTTTCTTGTTACAAATGGC	ACGTTGGATGCAGAATAGCCTGTTTTCCC	gagTGTTACAAATGGCTTTCAT
rs1034832	ACGTTGGATGCTACAGTTCCTCAATAGGAC	ACGTTGGATGTCATGGACACAGTTTTTAC	ctgTTCTGGCACTATTATTCAA
rs12681366	ACGTTGGATGCAGACACCTTCTGTTAGTGG	ACGTTGGATGGACCAATCAGTCTATGCACG	aaTGGGGACGTTCTTTCAT
rs957448	ACGTTGGATGAGTCCTAGCTAACATAACCC	ACGTTGGATGTAGACAGTATTCCTGAGGAG	gAGCTAACATAACCCACCTTC
rs11774066	ACGTTGGATGTAGTCACATCTCTGGAGTTC	ACGTTGGATGAGATGTGAGGCATCTGTCTG	gAGAAAGCATGTCTAGACC
rs1487022	ACGTTGGATGAGCTGGAAGTCAAAGACTTG	ACGTTGGATGGTCTGCTTTTTCAACCTGGAT	CTTGTAGATTTAGAATCCTGATAGTAA
rs1993392	ACGTTGGATGACAGAATTGTGAAACCACCC	ACGTTGGATGGCAGCCTTTTCACAACCTGG	ACTTTGAAATAGGGGCA
rs7845615	ACGTTGGATGTTCAATTTCCACCTTGCACGC	ACGTTGGATGAAGGCACCCTGATTTGGTAG	GAATTACCTTGTTTTGAATGG
rs7017252	ACGTTGGATGTGGGAACCTCAACACCTATG	ACGTTGGATGGAACCCAGATCTTTCTGAC	ccttgGCAAGGCCTTTAATATCTCG
rs327753	ACGTTGGATGAGGAAACCCCTCTCATCTAC	ACGTTGGATGGCAGCAAAGATACTGAATGG	CTCTCATCTACTCTCCACT
rs2990600	ACGTTGGATGGAGAAGATCAGACTCATCCC	ACGTTGGATGGAAGTATACTCCAAAATCTG	GATGTCTGGGTTAGCAC
rs408960	ACGTTGGATGCTGGAAGAGGAGCAGTATAA	ACGTTGGATGGCAATAGATGATCCTCAAGC	GGAGCAGTATAAAAAATGAGTT

rs324475	ACGTTGGATGCCCAATCAGGGTGCATTAAG	ACGTTGGATGGATGTGAAGAGCCAGTTTTTC	tttatTCACAAATCTTTGCATGACACT
rs77401103	ACGTTGGATGTGCTTTCCATATTTTTGACC	ACGTTGGATGGGGTCTATTAGTTAAAAGTG	ggggCCATATTTTTGACCCAGGAA
rs542733	ACGTTGGATGACCAAAGCTGACTCTTTGGG	ACGTTGGATGGTTCACAAAATTTTAAGGTC	AGGTTACAACCCTGAAG
rs498010	ACGTTGGATGATCCAGCACACTGCGCATAG	ACGTTGGATGACTACCAACCATTGACTGGC	CTCTCGAGTCGGAGT
rs35825512	ACGTTGGATGATAACCATTCCCCAGTAAAGG	ACGTTGGATGGTCTCACCTTATACCTTGCC	CCCAGTAAAGGATCAGTGT
rs7863754	ACGTTGGATGTGCTGGCAAGAATGTAGAGG	ACGTTGGATGTTCTCCACAGTGGCTGCATC	aagcATGTAGAGGAATTGAAGCCCT
rs7871395	ACGTTGGATGACCTCCTTCCCTGCTAGAAT	ACGTTGGATGCCAGGCAGTCTCTAAATAAG	gaTTCCTGCTAGAATTCATTC
rs10512248	ACGTTGGATGGCAGGAGAAAAGTGGAAAGC	ACGTTGGATGAGCCAGTCTGGTGTCTGTG	AAACTGGAAAGCCATTTAC
rs28361526	ACGTTGGATGTGAACACTACGTCCTTAGTCC	ACGTTGGATGCTACCAGAAGCTGGGAATCG	AATTGTATGTTTGTATCCGT
rs13294988	ACGTTGGATGCATCCCACCTTACTCTCAGC	ACGTTGGATGAAGAGGAAAGGTTGTGGAGG	AGGTAGTGAAAAGTACTGTTT
rs474558	ACGTTGGATGCCGTCATCCATTCCCTTAGTG	ACGTTGGATGCCAGGCTATGATGATGATGC	ggaaTTGTTACTCAAAGTGTGGT
rs6585429	ACGTTGGATGTCTAGAGCAAACGTCCTGTG	ACGTTGGATGAATGCCCGAGTTAGTCAACC	atGCTGGGCACGGGGTC
rs12792211	ACGTTGGATGGCCCATGTTATTCCCTCTAC	ACGTTGGATGCTCTCTTCCCTGTCTTGATG	ccTCTCTGGGCCAGCTC
rs3741442	ACGTTGGATGTGTGCACAAATGCCCTAACC	ACGTTGGATGCTTCCTTCTACACCCCAATC	caccAATGCCCTAACCCAACAGTC
rs705704	ACGTTGGATGCAAGTGCTTAGACCGAAGGC	ACGTTGGATGCCTCTTCGTAATCCTACACC	TTCTCTGACAGTCCTTCTA
rs2304269	ACGTTGGATGTTTTGCGGTGAGGCGTTGAC	ACGTTGGATGCAAACCTCCTCCGGAAACTC	cccttACCACGCCCATATGAA
rs7967428	ACGTTGGATGCAGCCACCTTAAAATACCAC	ACGTTGGATGCCATTCCCTCAAAGCTTGTC	tATGAAGCAATTAATGTTTCATG
rs2188380	ACGTTGGATGCCACATTCTTCCCCAGCATT	ACGTTGGATGTAAGACCCCCAGTTTGTGGC	gGCATTTGGAATGGTCAATA
rs12229654	ACGTTGGATGTTATGCATAGGGTACCAGGC	ACGTTGGATGGTTTTGGAGAAAGGTACTIONG	GTTTGAAATAATACAAATAATTTCCATA
rs4766453	ACGTTGGATGCTATGTATTTAGGCACTGGG	ACGTTGGATGTCTGCAACAGCAGCAGATGG	gggaGAGGGCTGGCTTGATTC
rs11066150	ACGTTGGATGGCATTGAGAATGGGATTGAG	ACGTTGGATGAAAAACCAGTTCAGAAGAC	TGGTTTTATTTTTTATATAGTTATTGTC
rs12229892	ACGTTGGATGGATGACTAGATTTAGGCTCC	ACGTTGGATGGAGGTTTLAGAGATACCCAAG	cctaCAATTCCAGGCACTCACACTCA
rs9545308	ACGTTGGATGCAAAAAGGTGATCCAGGTCTC	ACGTTGGATGGGAGCTTCCAAGGTCAGTAA	aggttATCCAGGTCTCTTAGAATAA
rs1168980	ACGTTGGATGATTGAGTCCTGTGCCACAAC	ACGTTGGATGCAATGCTGCATATGTGTACC	aacgCAACTCACACACGCA
rs17103683	ACGTTGGATGAGGAACACGTAGGTCAGAAG	ACGTTGGATGGTGTTCCTTTTCAGCTCAG	ccacaAAGTGGACAAAAGCAGACA
rs1956424	ACGTTGGATGGTTATGCTTCTTATTTCCC	ACGTTGGATGAACAGCTTGTGAGGGTGAAC	ctGTCACTCCCCTGTCC

rs10133673	ACGTTGGATGCAGAGTCAGGGTTCATAGTC	ACGTTGGATGTCCTTCGGAGCTCCTTATTC	ggccGGGTTTCATAGTCACCACAT
rs7148069	ACGTTGGATGTACTGCTATTGCAATCACCC	ACGTTGGATGGATGCCAAACTTTTCTTAGAG	cAATTTTGCCTCCACC
rs10134081	ACGTTGGATGCTTCCCTTTCATCACTGGAC	ACGTTGGATGAAAGGCAAGTGCTAATGCC	CCTCCCTGTTGCTCC
rs9671386	ACGTTGGATGGTGTGGCCTGGAATGTAA	ACGTTGGATGGTGACTCTTCAGATAGTAGC	tctgTTCTCTTGTTTTTCAACTCC
rs1243572	ACGTTGGATGTTCCCTCAGTAAGCAGCTTG	ACGTTGGATGTTCCAATTGGTCTGTTTCCC	cttcgTTGTGCAAAGCTCACTGCATTA
rs1243573	ACGTTGGATGAGACAAGCTGCTTACTGAGG	ACGTTGGATGTCTTCTTCCCACTGCTTAG	GGGAAGGGCTAGGAC
rs78512626	ACGTTGGATGAACTGCTGTAAGGTCAGCTC	ACGTTGGATGCAAGGAATAGCAATGTGGAG	CTGCTATGAGGTTTTTTTTTTC
rs2289187	ACGTTGGATGTAATAACAACCTGCCCGTATG	ACGTTGGATGGCCAAAGTCAAGAATGAGG	gggGCCCGTATGGTGACA
rs6495117	ACGTTGGATGTCTCCTGGGCAAGTGTATGT	ACGTTGGATGGCAGATGTCTGATGTGTATC	tCAAGTGTATGTGTGCATGG
rs2283487	ACGTTGGATGACTTTGCTCTGGAAGAAGGG	ACGTTGGATGAAGCTTTGGAGGTGCTCCAG	GGTTTTCCAGATGGCTC
rs17136624	ACGTTGGATGTGCTCAAGCACATTCCTTCG	ACGTTGGATGGTTCTCTGAAAAGGCGCTG	ctATTCCTTCGTGTTCAAGTATA
rs4786640	ACGTTGGATGGTCTCTCCCTTGAATAAAG	ACGTTGGATGTTTCATCTACGCTCCATGGG	ATGTCTGAGTTTTTCTCCTCAA
rs7198766	ACGTTGGATGTCCTGTCTGGGCTCCTAAA	ACGTTGGATGGACAGCACATATGTGTGCTA	ggtcTGCCCTGCCAGACC
rs7188937	ACGTTGGATGCTTTTTAAGTGCCACCGACC	ACGTTGGATGACAGGTTGTGGAAGATCCTC	gCATGTCCAATGTATCCTCTTC
rs217181	ACGTTGGATGGGGTTGAGCACATTGTGAC	ACGTTGGATGGCTTACAGATTCAAGAATCC	gggttAGCACATTGTGAGTGGTTA
rs2872615	ACGTTGGATGTTCTCATGGCTGCTGGTATC	ACGTTGGATGAGGATAAAGCTGCGTGAGAC	gcgGCATGGCTCCAATCTC
rs1880646	ACGTTGGATGGCATGGGTACTTCTTTACAC	ACGTTGGATGCTTCCGCCCATATGTATCAG	GAATGTGAATGCACATGTGTA
rs4968247	ACGTTGGATGCCACATCTTAATGGTCCAGG	ACGTTGGATGCTCAATGTACTTCACCCCTC	ttGGGTCCCAAAGGAGA
rs1838105	ACGTTGGATGGCATTTCATTATGGGTGGAC	ACGTTGGATGTTCTGCTCTTTGGTTCCTGC	gaTGGACTGATTGAAGTGA
rs12951993	ACGTTGGATGTTGCCAGATGAGCATGATCC	ACGTTGGATGCTGCACAAGGCAAACCTGAC	ATGTCCAATTCTCTGAAATC
rs227731	ACGTTGGATGACCTTGAGTATGGTATGAC	ACGTTGGATGGAAAGCCAGCTTATCTGTTAC	gggGATGACTTTTTAGATACCACA
rs3903236	ACGTTGGATGCACAGAAGATGCAGTAAACC	ACGTTGGATGTCTCCCTACATGAAATATGG	AGAAGATGCAGTAAACCATTAAATA
rs79280643	ACGTTGGATGAGCTGCTACTATGAAGTTGG	ACGTTGGATGTATTTGCTCTTTGGGGCCTC	GAACTTGATATTGTGACTGTA
rs117386717	ACGTTGGATGCTCCATTTCTCTTTGATTCCG	ACGTTGGATGGTAACTGTCACATCCACTAC	AAATGGTTTTATTCAAAAAGGA
rs739461	ACGTTGGATGGATCACACGAGATATTCAGC	ACGTTGGATGGATGAGCTATAATCAGAGTC	AAACATTTTCTTTCCATAGAAG
rs6129653	ACGTTGGATGCAGCTATGGTCAGAGGGAG	ACGTTGGATGTGCAGGGTAGAGTGTGCGT	ccccCTATGGTCAGAGGGAGTGGCTA

rs6126344	ACGTTGGATGACTAATCCCAAGGACCTCAC	ACGTTGGATGTCACTTTCTGGAGAAGGCC	CCTTGCCCGGTGACC
rs2018054	ACGTTGGATGGTCTACTTTCTATGCAGACAC	ACGTTGGATGTCCCAGCAACTTGGCTTTCC	ggttATCTCTCTTTCTTTTCCCCAC
rs933150	ACGTTGGATGACTGGGTCTGTGCACAGTAG	ACGTTGGATGATGAGCATTGATAACGGCCC	cccgtTCTGTGCACAGTAGACCTACTA
rs7287092	ACGTTGGATGTGGAAACCTTGAAGTGGGG	ACGTTGGATGAGTCATCCTTCGGTTCTCAG	ACTGAGGGGAGGGTC
rs2073764	ACGTTGGATGTTACCAGGGACTTGGTCTC	ACGTTGGATGGAGGACCTTAGACCCAAGTG	CCTCCTGCCAGCTGC
rs8135014	ACGTTGGATGATGTGCCATGTCTACTGTC	ACGTTGGATGTGACTTGGTCGGGTACATGC	TACCTCCCAGCCACC
rs36604	ACGTTGGATGAATGTCTCAAAGGAACCAC	ACGTTGGATGTCCGTGTGGACAACCTAAGG	GGGCTTTAAGACCCC
rs5763674	ACGTTGGATGCTCATCCCAATCATGGTGGC	ACGTTGGATGTACTGCATTCCCTCTGACCTC	gggCATGGTGGCTCATCA
rs11089442	ACGTTGGATGTGCTGTTGTCAGAAGGTGTC	ACGTTGGATGAAGGCGCACATGAACCATTC	ccGATCGACCCGCTCCT
rs2839998	ACGTTGGATGCTCCAACACCCACAGCATTG	ACGTTGGATGCCTGGTTTCTGAGTAAAGGC	ctTCTCCCTGTGATAGCTT
rs2072196	ACGTTGGATGAGAGGAAATCCAAGACCCC	ACGTTGGATGGGATGACTGAGCAGAAGAAC	cttTCGCCTCCAATGTAAA
rs117353193	ACGTTGGATGCTAGCTACTACCAGTATGGC	ACGTTGGATGAGTTTGTCCACCACGCTGTC	GTCTCCACCAGAAGC
rs5753388	ACGTTGGATGCAATTACAACTAATGTCAC	ACGTTGGATGACTAACCCTGCATTTTTGG	ACAACTAATGTCACTTGTA
rs1003480	ACGTTGGATGGGCAGAAGTGATAGTAATCC	ACGTTGGATGCCACTACCCTGAATATGC	GATAGTAATCCAGGTGGAG
rs2073856	ACGTTGGATGCACCTATGCTATCACTACCC	ACGTTGGATGCACCCAGCATGGTCCTTTG	TTAAAGGGCAGAGGGG
rs17220418	ACGTTGGATGTACAGATTGAGAGCTTCTGC	ACGTTGGATGCCAGCCACAATCACTCTATG	GCTTCTGCTATTATTCCATTA
rs2006771	ACGTTGGATGTTCTCTCCTTCCTGTCCTGC	ACGTTGGATGGGTGCCACATGAACCAAGAC	TCCTTCACGCAGAGC
rs78212183	ACGTTGGATGCTTGGCCATCATTATCTACC	ACGTTGGATGTCCTGCAAAGCAACTTGAGG	gaccTCATTATCTACCCAATGCCT
rs5756130	ACGTTGGATGCTTCCGCAGCTGTTTGATGG	ACGTTGGATGAGCTGGAGATGGACCTGAAG	cctcaGCAGCTGTTTGATGGCTTCGTC
